A:	HUMAN NECESSITIES
A61:	MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K:	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K6/00:	Preparations for dentistry
A61K6/00A:	. Compositions characterised by physical properties
A61K6/00A1:	. . by refractive index
A61K6/00A2:	. . by particle size
A61K6/00A3:	. . by retraction, e.g. compositions for widening the sulcus for making dental impressions or removing teeth
A61K6/00A4:	. . Self-expanding, e.g. for filling teeth
A61K6/00A5:	. . Protective coating for natural or artificial teeth, such as sealing, dye coating, varnish
A61K6/00A6:	. . Compositions for detecting or measuring, e.g. contact points, irregularities on natural or artificial teeth
A61K6/00B:	. Chemical means for temporarily or permanently fixing teeth, palates or the like
A61K6/00B1:	. . containing cyanoacrylates
A61K6/00B2:	. . containing organic phosphorus derivatives[N0401]
A61K6/00B25:	. . containing organic sulfur derivatives[N0401]
A61K6/00B3:	. . Preparations for stabilising dentures in the mouth
A61K6/00C:	. Primers adhesive primers A61K6/00B
A61K6/00D:	. Use of preparations for dental root treatment
A61K6/00D1:	. . Cleaning; Disinfecting
A61K6/00D2:	. . Filling; Sealing
A61K6/00D3:	. . Apical treatment
A61K6/00D4:	. . in combination with dental implants
A61K6/00E:	. Preparations for dentistry characterised by the presence of organic or organo-metallic additives
A61K6/00E1:	. . Cationic, anionic or redox initiators
A61K6/00E2:	. . Photochemical radical initiators
A61K6/00E3:	. . Thermal radical initiators
A61K6/00E4:	. . Dyes
A61K6/00E4B:	. . . photochromic
A61K6/00E4D:	. . . thermochromic
A61K6/00E5:	. . Medicaments; Drugs
A61K6/00F:	. Preparations for dentistry characterized by the presence of inorganic additives
A61K6/00F1:	. . Fillers
A61K6/00F1A:	. . . comprising nitrogen-containing compounds
A61K6/00F1B:	. . . comprising sulfur-containing compounds
A61K6/00F1C:	. . . comprising phosphorus-containing compounds
A61K6/00F1C1:	. . . . Apatite
A61K6/00F1D:	. . . comprising silicon-containing compounds
A61K6/00F1E:	. . . Glass
A61K6/00F2:	. . Pigments
A61K6/00F3:	. . Initiators
A61K6/02:	. Use of preparations for artificial teeth, for filling or for capping teeth
A61K6/027:	. . Use of non-metallic elements or compounds thereof, e.g. carbon non-metallic elements per se C01B
A61K6/027C:	. . . Glass-ceramic-composites
A61K6/027D:	. . . Glasses
A61K6/02A:	. . Ceramics
A61K6/02A1:	. . . comprising manganese oxide
A61K6/02A10:	. . . comprising transition metal oxides
A61K6/02A11:	. . . Leucite
A61K6/02A2:	. . . comprising magnesium oxide
A61K6/02A3:	. . . comprising beryllium oxide
A61K6/02A4:	. . . comprising chromium oxide
A61K6/02A5:	. . . comprising iron oxide
A61K6/02A6:	. . . comprising titanium oxide
A61K6/02A7:	. . . comprising zirconium oxide
A61K6/02A8:	. . . comprising hafnium oxide
A61K6/02A9:	. . . comprising rare earth metal oxides
A61K6/02B:	. . Cermet-composites
A61K6/033:	. . . Phosphorus compounds, e.g. apatite
A61K6/04:	. . Use of metals or alloys
A61K6/04A:	. . . Rare earth metals
A61K6/04B:	. . . Noble metals
A61K6/05:	. . . Amalgams
A61K6/06:	. . Use of inorganic cements (cements per se C04B)
A61K6/06A:	. . . Phosphorus compounds, e.g. apatite[N0401]
A61K6/06A1:	. . . . Monomers[N0401]
A61K6/06A2:	. . . . Macromonomers; Oligomers[N0401]
A61K6/06B:	. . . Portland cements
A61K6/06C:	. . . Silicates
A61K6/06D:	. . . Pozzolans
A61K6/06E:	. . . Calcium sulfates/gypsum
A61K6/06F:	. . . Al-cements
A61K6/06G:	. . . Ca-Al-sulfate-cements
A61K6/06H:	. . . Phosphate cements apatite A61K6/033
A61K6/06J:	. . . Ammonium cements
A61K6/06K:	. . . Zeolite
A61K6/06L:	. . . Quartz or SiO2
A61K6/06M:	. . . Carbonates
A61K6/06N:	. . . Calcium oxide
A61K6/06P:	. . . comprising zirconium oxide
A61K6/06Q:	. . . comprising chromium oxide
A61K6/06R:	. . . comprising carbides
A61K6/08:	. . Use of natural or synthetic resins
A61K6/083:	. . . Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
A61K6/083M:	. . . . Polycarboxylate cements or glass ionomer cements
A61K6/087:	. . . Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61K6/09:	. . . . Polyurethanes
A61K6/093:	. . . . Polyorganosilicon compounds
A61K6/097:	. . . Polysaccharides
A61K6/10:	. Compositions for taking dental impressions
A61K6/10B:	. . containing polyorganosilicon compounds
A61K6/10D:	. . containing alginates[N0401]
A61K6/10F:	. . containing polyethers[N0401]
A61K6/027B:	. . . Gypsum
A61K6/083B:	. . . . characterised by organic or organo-metallic additives
A61K6/083B1:	. . . . . characterised by organic phosphorus derivatives[N0401]
A61K6/083B2:	. . . . . characterised by organic sulfur derivatives[N0401]
A61K6/083B3:	. . . . . characterised by carboxylic acid derivatives (A61K6/083M takes precedence)[N0401]
A61K6/083D:	. . . . characterised by inorganic additives
A61K6/083D1:	. . . . . Apatite[N0401]
A61K6/083G:	. . . . Halogen-containing polymers
A61K6/083K:	. . . . Cyanoacrylate polymers
A61K7/00:	IPC7 Cosmetics or similar toilet preparations (casings or accessories for storing or handling of solid or pasty toilet or cosmetic substances A45D40/00)
A61K7/00M:	. characterised by a special physical form
A61K7/11:	. . [N: IPC7] Preparations for fixing the hai
A61K7/11B:	. . .  characterised by the propellant
A61K7/13:	. . [N: IPC7] Preparations for dyeing the hai
A61K7/13B:	. . .  containing direct dyestuffs
A61K7/13B1:	. . . .  Azo dyes
A61K7/13B3:	. . . .  Macromolecular dyes; Reaction products of dyes with monomers or with macromolecular compounds
A61K7/13D:	. . .  containing phenolic or phenylamine dyes
A61K7/13F:	. . .  containing anthraquinone dyes
A61K7/13K:	. . .  containing heterocyclic dyes
A61K7/13K4:	. . . .  containing nitrogen[N9610]
A61K7/13M:	. . .  containing metal salts or complexes (A61K7/13B1 takes precedence)
A61K7/13P:	. . .  containing dyes of plant or animal origin
A61K7/13R:	. . .  containing nitro dyes
A61K7/15:	. .  IPC7 Shaving preparations (soaps or detergent compositions, e.g. shaving soaps, C11D)
A61K7/15B:	. . .  Shaving lotions; After-shaves; Lotions for electro-shaving
A61K7/15D:	. . .  Aerosol shaving foams
A61K7/16:	. [N: IPC7] Preparations for cleaning the teeth or mouth, e.g. tooth-pastes; Mouthwashes
A61K7/16B:	. .  containing inorganic compounds
A61K7/16D:	. .  containing organic compounds
A61K7/16D14:	. . .  Macromolecular compounds
A61K7/16D14D:	. . . .  Polysaccharides; Derivatives thereof
A61K7/16D16:	. . .  Organic compounds according to two or more of the groups A61K7/16D2 to A61K7/16D14, e.g. dyes for disclosing dental plaque
A61K7/16D16B:	. . . .  Dyes
A61K7/16D16B1:	. . . . .  for colouring dental plaque, e.g. for disclosing
A61K7/16D2:	. . .  Oxygen compounds[C9410]
A61K7/16F:	. .  containing products other than of plant or animal origin, with undetermined constitution
A61K7/16P:	. .  characterised by a special physical form[N9411]
A61K7/18:	. . [N: IPC7] Preparations containing fluorine compounds
A61K7/18B:	. . .  Organic fluorides
A61K7/18D:	. . .  Inorganic fluorides, e.g. InZrF7
A61K7/02:	. [N: IPC7] Make-up materials; Preparations for removing them; Body powders
A61K7/20:	. . [N: IPC7] Preparations containing compounds releasing oxygen or chlorine
A61K7/22:	. . [N: IPC7]
A61K7/30:	. . [N: IPC7] Preparations for cleaning dentures
A61K7/32:	. [N: IPC7] Anti-perspirants or body deodorant
A61K7/32M:	. .  characterised by compounds not provided for by groups A61K7/32P to A61K7/38D2
A61K7/32P:	. .  containing metal salts other than Zr, Zn or Al
A61K7/32Q:	. .  containing macromolecular compounds, e.g. ion-exchange resins
A61K7/32T:	. .  characterised by a special physical form, e.g. aerosols, foams
A61K7/34:	. . [N: IPC7] Preparations containing zirconium compounds
A61K7/36:	. . [N: IPC7] Preparations containing zinc compounds
A61K7/38:	. . [N: IPC7] Preparations containing aluminium compounds
A61K7/38B:	. . .  Organic compounds, e.g. salts of organic acids, complexes, organo-aluminium compounds
A61K7/38D:	. . .  Mixed salts or complexes, e.g. aluminium zirconium halides
A61K7/38D2:	. . . .  Alums
A61K7/04:	.  IPC7 Manicure or pedicure compositions (A61K7/48Z3 takes precedence)[C0007]
A61K7/40:	. [N: IPC7] Barrier compositions; Chemical agents brought into direct contact with the skin of living human or animal bodies for affording protection against external influences, e.g. sunlight, X- or other active rays, corrosive materials, bacteria, insect sting
A61K7/42:	. . [N: IPC7] Tropical sun or radiation screening or tanning preparations
A61K7/42C:	. . .  containing inorganic U.V. absorbers
A61K7/42P:	. . .  containing organic U.V. absorbers
A61K7/42S:	. . .  Preparations containing organic macromolecular U.V. absorbers; Reaction products of U.V. absorbers with monomers or with macromolecular compounds
A61K7/42T:	. . .  U.V. absorbers according to two or more of the preceding groups A61K7/42C to A61K7/42S
A61K7/42T2:	. . . .  Carbocyclic compounds (A61K7/42P12 takes precedence)
A61K7/46:	. [N: IPC7] Formulations and additives for perfume composition
A61K7/46K:	. .  Perfumes absorbed or entrapped into a solid carrier, e.g. inclusion compounds[N0003]
A61K7/46K2:	. . .  Perfumes covalently linked to a carrier molecule, e.g. pro-fragrances[N0003]
A61K7/46P:	. .  Perfumes in a special physical form, e.g. emulsions, impregnated tissues[N0003]
A61K7/46T:	. .  Deodorant or antibacterial perfumes[N0003]
A61K7/48:	. [N: IPC7] Preparations for the care of the ski
A61K7/48A:	. .  containing inorganic compounds
A61K7/48C:	. .  containing organic compounds
A61K7/48C14:	. . .  heterocyclic
A61K7/48C14D:	. . . .  with one nitrogen atom as the only heteroatom
A61K7/48C16:	. . .  Carbohydrates
A61K7/48C2:	. . .  Hydrocarbons
A61K7/48C26:	. . .  Compounds according to more than one of the preceding groups A61K7/48C2 to A61K7/48C24[C9409]
A61K7/48C26F:	. . . .  Antibiotics
A61K7/48C4:	. . .  containing oxygen
A61K7/48C4D:	. . . .  Alcohols; Phenols
A61K7/48C4D2:	. . . . .  Alcohols having more than seven carbon atoms in an unbroken chain[N9610]
A61K7/48C4F:	. . . .  Acids; Salts thereof
A61K7/48C4F3:	. . . . .  Hydroxycarboxylic acids; Ketocarboxylic acids[N9610]
A61K7/48C4K:	. . . .  Esters of carboxylic acids[C9610]
A61K7/48C6:	. . .  containing nitrogen[C9807]
A61K7/48C6P:	. . . .  Aminocarboxylic acids; Salts; Esters or N-acylated derivatives thereof
A61K7/48C8:	. . .  containing sulfur (A61K7/48C6P4 takes precedence)
A61K7/48N:	. .  containing organic macromolecular compounds
A61K7/48N12:	. . .  obtained by reactions involving only carbon-to-carbon unsaturated bonds[N0003]
A61K7/48N12K:	. . . .  Homo- or copolymers of acrylic type, i.e. as defined in C08L33/00[N0003]
A61K7/48N14:	. . .  obtained by reactions otherwise than those involving only carbon-to-carbon unsaturated bonds[N0003]
A61K7/48N16:	. . .  Polysiloxanes[N0003]
A61K7/48N16B:	. . . .  saturated[N0003]
A61K7/48N16F:	. . . .  containing other atoms than carbon and hydrogen besides the atoms of the backbone[N0003]
A61K7/48N16F2:	. . . . .  containing oxygen[N0003]
A61K7/48N16F6:	. . . . .  containing nitrogen[N0003]
A61K7/48N16F8:	. . . . .  containing sulfur[N0003]
A61K7/48N18:	. . .  Block copolymers[N0003]
A61K7/48N18M:	. . . .  containing a polycondensate segment[N0011]
A61K7/48N2:	. . .  cationic; basic; amphoteric[C0007] Note: Not used, see Warning 5 after the subclass title
A61K7/48N22:	. . .  Graft copolymers[N0003]
A61K7/48N22B:	. . . .  the backbone being made of a natural polymer[N0003]
A61K7/48N22D:	. . . .  the backbone being made of a vinyl polymer[N0003]
A61K7/48N22F:	. . . .  the backbone being made of a polycondensate[N0003]
A61K7/48N34:	. . .  Macromolecular compounds according to more than one of the preceding groups A61K7/48N8 to A61K7/48N22[N0003]
A61K7/48N34F:	. . . .  cationic or amphoteric[N0003]
A61K7/48T:	. .  Oils, fats or waxes according to two or more of the preceding groups A61K7/48A to A61K7/48N34T
A61K7/48T4:	. . .  of animal origin
A61K7/48W:	. .  Preparations containing products of undetermined constitution; Derivatives or action products thereof
A61K7/48W2:	. . .  of inanimate origin
A61K7/48Z:	. .  Preparations according to two or more of the preceding groups A61K7/48A to A61K7/48W12
A61K7/48Z3:	. . .  characterised by colorant properties[N0003]
A61K7/48Z3B:	. . . .  Pigments; Dyes[N0003]
A61K7/48Z3B4:	. . . . .  iridescent; pearlescent[N0003]
A61K7/48Z3B8:	. . . . .  chromophoric; photochromic; phototropic[N0003]
A61K7/48Z5:	. . .  characterised by electromagnetic properties[N0003]
A61K7/48Z5E:	. . . .  Cosmetics treated by (ir)radiation[N0003]
A61K7/04D:	. . Preparations for treating or fortifying nails; Preparations for removing nail cuticles
A61K7/50:	. . [N: IPC7] Washing or bathing preparation
A61K7/50D:	. . .  Rubbing or scrubbing compositions; Abrasive compositions; Peeling compositions[N0003]
A61K7/50F:	. . .  Gas liberating or effervescent compositions
A61K7/50K:	. . .  based essentially on surface active compounds[N0007]
A61K7/50K10:	. . . .  Ternary mixtures of anionic, cationic and non-ionic compounds[N0007]
A61K7/50K12:	. . . . Ampholytes; Zwitterionic compounds (A61K7/50K2takes precedence)[N0007]
A61K7/50K12B:	. . . . .  Mixtures with anionin, cationic and non-ionic compounds[N0007]
A61K7/50K14:	. . . .  Surface active compounds containing phosphorus, e.g. lecithin, alkylphosphates (A61K7/50K12 takes precedence)[N0007]
A61K7/50K2:	. . . .  Surface active compounds containing fluorine[N0007]
A61K7/50K4:	. . . . Anionic compounds (A61K7/50K2takes precedence)[N0007]
A61K7/50K6:	. . . . Cationic compounds (A61K7/50K2takes precedence)[N0007]
A61K7/50K6B:	. . . . .  Quaternary ammonium compounds[N0007]
A61K7/50K6D:	. . . . .  Mixtures of anionic and cathionic compounds[N0007]
A61K7/50K8:	. . . . Non-ionic compounds (A61K7/50K2takes precedence)[N0007]
A61K7/50K8B:	. . . . .  Carbohydrates or derivatives[N0007]
A61K7/50K8D:	. . . . .  Amine oxides[N0007]
A61K7/50K8F:	. . . . .  Mixtures of compounds all of which are non-ionic[N0007]
A61K7/50K8G:	. . . . .  Mixtures of non-ionic and anionic compounds[N0007]
A61K7/50K8H:	. . . . .  Mixtures of non-ionic and cationic compounds[N0007]
A61K7/50T:	. . .  characterised by special physical form, e.g. microcapsules, tissues
A61K7/50T2:	. . . .  Microcapsules; Liposomes; Microspheres; Granules; Agglomerates; Matrixes[N0003]
A61K7/50Z:	. . .  Preparations according to more than one of the preceding groups[N0003]
A61K7/50Z4:	. . . .  Tissues; Wipes; Sponges[N0003]
A61K7/06:	. [N: IPC7] Preparations, e.g. lotions or powders, for care of the hair; Preparations to promote hair growth or to aid in hair removal, e.g. shaving preparation
A61K7/06A:	. . containing inorganic compounds
A61K7/06C:	. . containing organic compounds
A61K7/06C14:	. . . heterocyclic
A61K7/06C2:	. . . Hydrocarbons
A61K7/06C26:	. . . Compounds according to two or more of the preceding groupsA61K7/06C2toA61K7/06C22[N9409]
A61K7/06C26D:	. . . . Vitamins[N9610]
A61K7/06C4:	. . . containing oxygen
A61K7/06C4D:	. . . . Alcohols; Phenols
A61K7/06C4F:	. . . . Acids; Salts thereof
A61K7/06C4F3:	. . . . . Hydrocarboxylic acids; Ketocarboxylic acids[N9610]
A61K7/06C6:	. . . containing nitrogen
A61K7/06C6D:	. . . . Amines; Acylated derivatives thereof[C9409]
A61K7/06C6D3:	. . . . . Amides[N9409]
A61K7/06C6M:	. . . . Aminocarboxylic acids; Salts; Esters or N-acylated derivatives thereof
A61K7/06C6M4:	. . . . . containing sulfur
A61K7/06G:	. . containing organic macromolecular compounds
A61K7/06G12:	. . . obtained by reactions involving only carbon-to-carbon unsaturated bonds[N0003]
A61K7/06G12K:	. . . . Homo- or copolymers of acrylic type, i.e. as defined inC08L33/00[N0003]
A61K7/06G14:	. . . obtained by reactions otherwise than those involving only carbon-to-carbon unsaturated bonds[N0003]
A61K7/06G16:	. . . Polysiloxanes[N0003]
A61K7/06G16B:	. . . . saturated[N0003]
A61K7/06G16F:	. . . . containing other atoms than carbon and hydrogen besides the atoms of the backbone[N0003]
A61K7/06G16F2:	. . . . . containing oxygen[N0003]
A61K7/06G16F6:	. . . . . containing nitrogen[N0003]
A61K7/06G16F8:	. . . . . containing sulfur[N0003]
A61K7/06G18:	. . . Block copolymers[N0003]
A61K7/06G18M:	. . . .  containing a polycondensate segment[N0011]
A61K7/06G2:	. . .  non-ionic or anionic Warning: No longer used, see Warning 5 after the subclass title[C0007]
A61K7/06G22:	. . . Graft copolymers[N0003]
A61K7/06G22D:	. . . .  the backbone being made of a vinyl polymer[N0003]
A61K7/06G22D4:	. . . . .  grafted with a vinyl polymer[N0003]
A61K7/06G22D6:	. . . . .  grafted with a polycondensate[N0003]
A61K7/06G22F:	. . . .  the backbone being made of a polycondensate[N0003]
A61K7/06G34:	. . . Macromolecular compounds according to more than one of the preceding groupsA61K7/06G8toA61K7/06G22[N0003]
A61K7/06G34D:	. . . .  nonionic or anionic[N0003]
A61K7/06G34F:	. . . .  cationic or amphoteric[N0003]
A61K7/06G4:	. . .  cationic, basic, amphoteric Warning: No longer used, see Warning 5 after the subclass title[C0007]
A61K7/06N:	. .  Oils, fats, waxes according to two or more of the preceding groups A61K7/06A to A61K7/06G34T; Derivatives thereof, e.g. hydrogenation products thereof
A61K7/06Z:	. .  characterised by a special form, e.g. preparation coated on a comb[N0003]
A61K7/07:	. . [N: IPC7] Hair powder
A61K7/08:	. . [N: IPC7] Preparations for rinsing the hair
A61K7/08B:	. . .  Preparations for dry cleaning the hair
A61K7/08D:	. . .  Colouring shampoos or rinses
A61K7/09:	. . [N: IPC7] Preparations for waving or straightening the hair
A61K7/09B:	. . .  containing compounds capable of reducing the hair`s cystinic -S-S- bonds or oxidising the cysteinic -SH bonds
A61K7/09C:	. . .  containing organic compounds of phosphorus, titanium or zirconium
A61K7/09K:	. . .  containing only alkaline compounds
A61K7/09M:	. . .  containing compounds polymerising onto the hair, or containing macromolecular compounds reacting with the hair keratin`s reduced sulfide bonds
A61K7/09S:	. . .  with simultaneous dyeing
A61K7/135:	. . Preparations for bleaching the hair
A61K7/135B:	. . .  Preparations for removing dyes from the hair
A61K7/155:	. . Depilatories
A61K7/155K:	. . .  Preparations not degrading the hair by chemical action
A61K7/021:	. . [N: IPC7] Preparations containing skin coloran
A61K7/025:	. . . [N: IPC7] for lips
A61K7/047:	. . [N: IPC7] Nail coating removers
A61K8/00:	Cosmetic or similar toilet preparations
A61K8/02:	. characterised by special physical form
A61K8/02A:	. . [N: Specific forms not provided for by any of groups A61K8/02C to A61K8/14]
A61K8/02C:	. . Tissues; Wipes; Patches
A61K8/02F:	. . Face masks
A61K8/02H:	. . Liquid crystals[N0209]
A61K8/02M:	. . [N: Solid or semisolid forms]
A61K8/02M2:	. . . [N: Powders; Compacted Powders]
A61K8/02M2G:	. . . . [N: Granulated powders]
A61K8/02M4:	. . . [N: Sticks]
A61K8/02M5:	. . . [N: Distinct layers, e.g. core/shell sticks]
A61K8/02M5S:	. . . . [N: Striped compositions]
A61K8/02N:	. . [N: Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)]
A61K8/02N1:	. . . [N: Specific shapes or structures not provided for by any of the groups of A61K8/02N]
A61K8/02N2:	. . . [N: Explicitly spheroidal or spherical shape]
A61K8/02N3:	. . . [N: Platelets; Flakes]
A61K8/02N3L:	. . . . [N: Layered structure]
A61K8/02N3L3:	. . . . . [N: Characterized by the central layer]
A61K8/02N3L6:	. . . . . [N: Characterized by the sequence of layers]
A61K8/02N4:	. . . [N: Fibers; Fibrils]
A61K8/02N5:	. . . [N: Containing agglomerated particulates]
A61K8/02N6:	. . . [N: Porous; Hollow]
A61K8/02N7:	. . . [N: Matrix particles]
A61K8/02N7D:	. . . . [N: the particulate containing a solid-in-solid dispersion]
A61K8/02S:	. . [N: Micelles]
A61K8/02X:	. . [N: Liquid crystals]
A61K8/03:	. . Liquid compositions with two or more distinct layers
A61K8/04:	. . Dispersions; Emulsions
A61K8/04A:	. . . Gels
A61K8/04C:	. . . Suspensions
A61K8/04F:	. . . Aerosols; Foams
A61K8/04H:	. . . Microbeadlets; Microspheres; Granules; Microgranules[N0209]
A61K8/06:	. . . Emulsions
A61K8/06A:	. . . . [N: Oil-in-water emulsions]
A61K8/06B:	. . . . [N: Water-in-oil emulsions, e.g. Water-in-silicone emulsions]
A61K8/06C:	. . . . Microemulsions; Nanoemulsions[N0209][C0405]
A61K8/06F:	. . . . Multiple emulsions, e.g. water-in-oil-in-water
A61K8/06M:	. . . . [N: Microemulsions]
A61K8/11:	. . Encapsulated compositions
A61K8/11C:	. . . Microcapsules[N0209]
A61K8/11F:	. . . Nanocapsules[N0209]
A61K8/14:	. . Liposomes; Vesicles
A61K8/14C:	. . . Micelles[N0209]
A61K8/18:	. characterised by the composition
A61K8/19:	. . containing inorganic ingredients
A61K8/20:	. . . Halogens; Compounds thereof
A61K8/21:	. . . . Fluorides; Derivatives thereof
A61K8/22:	. . . Peroxides; Oxygen; Ozone
A61K8/23:	. . . Sulfur; Selenium; Tellurium; Compounds thereof
A61K8/24:	. . . Phosphorous; Compounds thereof
A61K8/25:	. . . Silicon; Compounds thereof
A61K8/26:	. . . Aluminium; Compounds thereof
A61K8/27:	. . . Zinc; Compounds thereof
A61K8/28:	. . . Zirconium; Compounds thereof
A61K8/29:	. . . Titanium; Compounds thereof
A61K8/30:	. . containing organic compounds
A61K8/31:	. . . Hydrocarbons
A61K8/31C:	. . . . Halogenated hydrocarbons
A61K8/33:	. . . containing oxygen
A61K8/34:	. . . . Alcohols
A61K8/34C:	. . . . . Alcohols having more than seven atoms in an unbroken chain
A61K8/34D:	. . . . . containing more than one hydroxy group
A61K8/34F:	. . . . . Phenols
A61K8/35:	. . . . Ketones, e.g. benzophenone
A61K8/35C:	. . . . . Quinones
A61K8/36:	. . . . Carboxylic acids; Salts or anhydrides thereof
A61K8/362:	. . . . . Polycarboxylic acids
A61K8/365:	. . . . . Hydroxycarboxylic acids; Ketocarboxylic acids
A61K8/368:	. . . . . with carboxyl groups directly bound to carbon atoms or aromatic rings
A61K8/36C:	. . . . . Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
A61K8/37:	. . . . Esters of carboxylic acids
A61K8/37C:	. . . . . the alcohol moiety containing more than one hydroxy group
A61K8/38:	. . . . Percompounds, e.g. peracids
A61K8/39:	. . . . Alkoxylated derivatives, i.e. derivatives containing from 2 to 10 oxyalkylene groups
A61K8/40:	. . . containing nitrogen
A61K8/41:	. . . . Amines
A61K8/41C:	. . . . . Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus
A61K8/41F:	. . . . . Indoanilines; Indophenol; Indoamines
A61K8/41H:	. . . . . Aminophenols
A61K8/41L:	. . . . . Quaternary ammonium compounds A61K8/35 takes precedence
A61K8/41R:	. . . . . containing nitro groups
A61K8/42:	. . . . Amides
A61K8/43:	. . . . Guanidines
A61K8/44:	. . . . Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
A61K8/44D:	. . . . . substituted by amido group(s)
A61K8/44G:	. . . . . aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
A61K8/44K:	. . . . . containing sulfur
A61K8/45:	. . . . Alkoxylatedderivatives, i.e. derivatives containing from 2 to 10 oxyalkylene groups
A61K8/46:	. . . containing sulfur
A61K8/46C:	. . . . containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
A61K8/46F:	. . . . containing sulfonic acid derivatives; Salts
A61K8/49:	. . . containing heterocyclic compounds
A61K8/49C:	. . . . with one nitrogen as the only hetero atom
A61K8/49C2:	. . . . . having five membered rings, e.g. pyrrolidone carboxylic acid
A61K8/49C2C:	. . . . . . having condensed rings, e.g. indol
A61K8/49C4:	. . . . . having six membered rings
A61K8/49C6:	. . . . . having sulfur as an exocyclic substituent, e.g. pyridinethione
A61K8/49F:	. . . . with more than one nitrogen as the only hetero atom
A61K8/49F1:	. . . . . Imidazoles or their condensed derivatives, e.g. benzimidazoles
A61K8/49F2:	. . . . . containing pyrimidine ring derivatives, e.g. minoxidil
A61K8/49F3:	. . . . . Triazoles or their condensed derivatives, e.g. benzotriazoles
A61K8/49F4:	. . . . . Triazines or their condensed derivatives
A61K8/49H:	. . . . with oxygen as the only hetero atom
A61K8/49H2:	. . . . . having 6-membered rings or their condensed derivatives, e.g. coumarin
A61K8/49L:	. . . . with sulfur as the only hetero atom
A61K8/49P:	. . . . Alkoxylated derivatives, i.e. derivatives containing from 2 to 10 oxyalkylene groups
A61K8/55:	. . . Phosphorus compounds
A61K8/55C:	. . . . Phospholipids, e.g. lecithin
A61K8/55F:	. . . . Alkoxylated derivatives, i.e. derivatives containing from 2 to 10 oxyalkylene groups
A61K8/58:	. . . containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
A61K8/58C:	. . . . Organosilicon compounds
A61K8/60:	. . . Sugars; Derivatives thereof
A61K8/60A:	. . . . Glycosides, e.g. rutin
A61K8/60B:	. . . . Alkylpolyglycosides; Derivatives thereof, e.g. esters
A61K8/60C:	. . . . Nucleosides; Nucleotides; Nucleic acids
A61K8/60F:	. . . . Alkoxylated derivatives, i.e. derivatives containing from 2 to 10 oxyalkylene groups
A61K8/63:	. . . Steroids; Derivatives thereof
A61K8/64:	. . . Proteins; Peptides; Derivatives or degradation products thereof
A61K8/64C:	. . . . Proteins of vegetable origin; Derivatives or degradation products thereof
A61K8/65:	. . . . Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
A61K8/66:	. . . . Enzymes
A61K8/67:	. . . Vitamins
A61K8/67C:	. . . . Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
A61K8/67F:	. . . . Vitamin B group
A61K8/67F3:	. . . . . Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde tocopheryl nicotinate A61K8/67L
A61K8/67H:	. . . . Ascorbic acid, i.e. vitamin C
A61K8/67L:	. . . . Tocopherol, i.e. vitamin E
A61K8/68:	. . . Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
A61K8/69:	. . . containing fluorine
A61K8/70:	. . . . containing perfluoro groups, e.g. perfluoroethers
A61K8/72:	. . containing organic macromolecular compounds
A61K8/73:	. . . Polysaccharides
A61K8/73C:	. . . . Cellulose; Quaternized cellulose derivatives
A61K8/73F:	. . . . Starch; Amylose; Amylopectin; Derivatives thereof
A61K8/73H:	. . . . Alginic acid; Salts thereof
A61K8/73L:	. . . . Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
A61K8/73P:	. . . . Chitin; Chitosan; Derivatives thereof
A61K8/73R:	. . . . Galactomannans, e.g. guar; Derivatives thereof
A61K8/73T:	. . . . Cyclodextrins
A61K8/81:	. . . obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K8/81C:	. . . . Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
A61K8/81C2:	. . . . . Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
A61K8/81C4:	. . . . . Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
A61K8/81E:	. . . . Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE
A61K8/81G:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether
A61K8/81H:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)
A61K8/81K:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
A61K8/81K2:	. . . . . Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
A61K8/81K4:	. . . . . Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
A61K8/81K6:	. . . . . Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
A61K8/81M:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly(methyl vinyl ether-co-maleic anhydride)
A61K8/81R:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
A61K8/81R2:	. . . . . Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers
A61K8/81R4:	. . . . . Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
A61K8/81T:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers
A61K8/81W:	. . . . Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers
A61K8/84:	. . . obained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
A61K8/85:	. . . . Polyesters
A61K8/86:	. . . . Polyethers
A61K8/87:	. . . . Polyurethanes
A61K8/88:	. . . . Polyamides
A61K8/89:	. . . . Polysiloxanes
A61K8/891:	. . . . . saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
A61K8/892:	. . . . . . modified by a hydroxy group, e.g. dimethiconol
A61K8/893:	. . . . . . modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone
A61K8/894:	. . . . . . modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
A61K8/895:	. . . . . containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
A61K8/896:	. . . . . containing atoms other than silicon, carbon, oxygen and hydrogen, e.g. dimethicone copolyol phosphate
A61K8/897:	. . . . . . containing halogen, e.g. fluorosilicones
A61K8/898:	. . . . . . containing nitrogen, e.g. amodimethicone, trimethyl silyl amodimethicone or dimethicone propyl PG-betaine
A61K8/899:	. . . . . . containing sulfur, e.g. sodium PG-propyldimethicone thiosulfate copolyol
A61K8/90:	. . . Block copolymers
A61K8/91:	. . . Graft copolymers
A61K8/92:	. . Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
A61K8/92C:	. . . of vegetable origin
A61K8/92F:	. . . of animal origin
A61K8/92H:	. . . of insects, e.g. shellac
A61K8/96:	. . containing material, or derivatives thereof of undetermined constitution
A61K8/96C:	. . . of inanimate origin
A61K8/97:	. . . of vegetable origin, e.g. plant extracts
A61K8/97C:	. . . . Pollen; Algae, Higher fungi
A61K8/98:	. . . of animal origin
A61K8/98C:	. . . . of mammals or bird
A61K8/98C2:	. . . . . Reproductive organs; Embryos, Eggs
A61K8/98C4:	. . . . . Blood, e.g. plasma
A61K8/98C6:	. . . . . Skin or skin outgrowth, e.g. hair, nails
A61K8/98C8:	. . . . . Milk; Derivatives thereof, e.g. butter
A61K8/98F:	. . . . of species other than mammals or birds
A61K8/98F2:	. . . . . Honey; Royal jelly, Propolis
A61K8/99:	. . . from micro-organisms
A61K9/00:	Medicinal preparations characterised by special physical form
A61K9/00L:	. [N: Galenical forms characterised by the drug release technique; Application systems commanded by energy]
A61K9/00L4:	. . [N: Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas]
A61K9/00L6:	. . Effervescent A61K9/00M18F takes precedence
A61K9/00L6B:	. . . Effervescent suppositories
A61K9/00L8:	. . [N: involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis (microelectromechanical systems A61K9/00Z8)]
A61K9/00M:	. [N: Galenical forms characterised by the site of application]
A61K9/00M12:	. . [N: Mammary glands, e.g. breasts, udder; Intramammary administration]
A61K9/00M14:	. . Nose
A61K9/00M15:	. . [N: Ear]
A61K9/00M16:	. . Eye, e.g. artificial tears
A61K9/00M16B:	. . . Ocular inserts, ocular implants
A61K9/00M18:	. . [N: Mouth and digestive tract, i.e. intraoral and peroral administration (rectal administration A61K9/00M6)]
A61K9/00M18B:	. . . [N: Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals]
A61K9/00M18B2:	. . . . [N: Chewing gums (non-medicinal aspects, preparing chewing gum A23G4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q11/00)]
A61K9/00M18D:	. . . [N: Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays]
A61K9/00M18E:	. . . Periodont
A61K9/00M18F:	. . . [N: Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus]
A61K9/00M18G:	. . . [N: Rumen, e.g. rumen bolus]
A61K9/00M20:	. . [N: Pulmonary tract; Aromatherapy]
A61K9/00M20B:	. . . Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/00M14; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/00M20; devices A61M
A61K9/00M20B3:	. . . . [N: for inhalation via a dry powder inhaler (DPI), e.g. comprising micronized drug mixed with lactose carier particles]
A61K9/00M20B5:	. . . . [N: for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions]
A61K9/00M20B6:	. . . . [N: comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler (MDI)]
A61K9/00M20N:	. . . [N: Lung surfactant, artificial mucus]
A61K9/00M22:	. . Brain, e.g. brain implants; Spinal cord
A61K9/00M3:	. . Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/00L8, A61K9/00M5B, A61K9/70D, A61K9/70E take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
A61K9/00M3B:	. . . [N: Non-human animal skin, e.g. pour-on, spot-on]
A61K9/00M5:	. . [N: Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)]
A61K9/00M5B:	. . . [N: Intradermal administration, e.g. through microneedle arrays, needleless injectors (mechanical aspects A61M)]
A61K9/00M5D:	. . . [N: Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for e.g. subcutaneous administration A61K9/00M5; brain implants A61K9/00M22; (coated) prostheses, catheters or stents A61L)]
A61K9/00M5F:	. . . [N: Blood substitute; Oxygen transporting formulations; Plasma extender]
A61K9/00M5G:	. . . [N: Parenteral nutrition; Parenteral nutrition compositions as drug carriers]
A61K9/00M6:	. . [N: Rectum, anus]
A61K9/00M8:	. . Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
A61K9/00M8B:	. . . [N: Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms]
A61K9/00M8D:	. . . [N: Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception]
A61K9/00Z:	. [N: Galenical forms not covered by A61K9/02 to A61K9/70E]
A61K9/00Z2:	. . [N: Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/00M18F; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/00Z6)]
A61K9/00Z4:	. . Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules, nanotubes fibres of the matrix type containing drug A61K9/70
A61K9/00Z6:	. . Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/00L6 takes precedence; eatable gels or foams A61K9/00M18B; oral mucosa adhesive forms A61K9/00M18D
A61K9/00Z8:	. . [N: Micromachined devices; Microelectromechanical systems (MEMS); Devices obtained by lithographic treatment of silicon; Devices comprising chips (intradermal microneedle arrays A61K9/00M5B; MEMS in general B81B7/02)]
A61K9/02:	. Suppositories; Bougies; Bases therefor; Ovules
A61K9/02K:	. . characterised by shape or structure, e.g. hollow layered, coated
A61K9/06:	. Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
A61K9/08:	. Solutions; composition of solutions A61K47/00
A61K9/10:	. Dispersions; Emulsions; A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
A61K9/107:	. . Emulsions; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
A61K9/107D:	. . . Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/00M5F takes precedence
A61K9/113:	. . . Multiple emulsions, e.g. oil-in-water-in-oil; A61K9/00M5F takes precedence
A61K9/12:	. . Aerosols; Foams [N: (A61K9/00M14, A61K9/00M18B, A61K9/00M18D, A61K9/00M20B take precedence; spray-films A61K9/70D)]
A61K9/127:	. . Liposomes
A61K9/127B:	. . . Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers see also A61K47/48W6D
A61K9/127B2:	. . . . with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; cationic lipid/DNA complexes see also A61K47/48H4F
A61K9/127B4:	. . . . Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances polymers grafted or coated on phosphatidyl liposomes A61K9/127B, on non-phosphatidyl liposomes A61K9/127B2
A61K9/127K:	. . . Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
A61K9/127M:	. . . Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
A61K9/127N:	. . . Globules of milk or constituents thereof
A61K9/127P:	. . . Processes for preparing; Proliposomes
A61K9/127P2:	. . . . Post-loading, e.g. by ion or pH gradient
A61K9/12B:	. . . Foams; Dry foams edible foams A61K9/00M18B
A61K9/12D:	. . . characterised by the propellant
A61K9/14:	. Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
A61K9/14H:	. . Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers co)spray-dried products A61K9/16, (colyophilised products A61K9/19; the carrier being chemically bound to the active ingredient A61K47/48
A61K9/14H2:	. . . with inorganic compounds
A61K9/14H4:	. . . with organic compounds
A61K9/14H6:	. . . with organic macromolecular compounds
A61K9/14H8:	. . . with compounds of unknown constitution, e.g. material from plants or animals with oils, fats, waxes, shellac A61K9/14H4
A61K9/16:	. . Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing, multiple) emulsion solvent evaporation or extraction A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated microparticles A61K9/50M; nanoparticles A61K9/51
A61K9/16H:	. . . Excipients; Inactive ingredients
A61K9/16H2:	. . . . Inorganic compounds
A61K9/16H4:	. . . . Organic compounds, e.g. phospholipids, fats
A61K9/16H4B:	. . . . . Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
A61K9/16H6:	. . . . Organic macromolecular compounds
A61K9/16H6B:	. . . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K9/16H6D:	. . . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
A61K9/16H6D4:	. . . . . . Polyesters, e.g. poly(lactide-co-glycolide)
A61K9/16H6F:	. . . . . Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/16H4B
A61K9/16H6H:	. . . . . Proteins, e.g. albumin, gelatin
A61K9/16H8:	. . . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/16H4
A61K9/16K:	. . . with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/50K
A61K9/16K2:	. . . . having a drug-free core with discrete complete coating layer containing drug adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/14H; with further drug-free outer coating A61K9/50K2; drug conjugated to non-active particles A61K47/48W8
A61K9/16P:	. . . Processes
A61K9/16P2:	. . . . resulting in pure drug agglomerate optionally containing up to 5% of excipient
A61K9/16P4:	. . . . resulting in granules or microspheres of the matrix type containing more than 5% of excipient
A61K9/19:	. . lyophilised, i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/16P; solid oral dosage forms made by lyophilisation A61K9/20P; lyophilisation additives A61K47/00
A61K9/20:	. Pills, tablets, [N: discs, rods (A61K9/00L4, A61K9/00L6, A61K9/00M18B, A61K9/00M18F take precedence; for reconstitution of a drink a61K9/00Z6)]
A61K9/20H:	. . Excipients; Inactive ingredients
A61K9/20H2:	. . . Inorganic compounds
A61K9/20H4:	. . . Organic compounds, e.g. phospholipids, fats
A61K9/20H4B:	. . . . Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
A61K9/20H6:	. . . Organic macromolecular compounds
A61K9/20H6B:	. . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K9/20H6D:	. . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
A61K9/20H6D2:	. . . . . Silicones; Polysiloxanes
A61K9/20H6D4:	. . . . . Polyesters, e.g. poly(lactide-co-glycolide)
A61K9/20H6D6:	. . . . . Polyamides; Polyaminoacids, e.g. polylysine
A61K9/20H6F:	. . . . Polysaccharides, e.g. alginate, gums; Cyclodextrin
A61K9/20H6F2:	. . . . . Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
A61K9/20H6F4:	. . . . . Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
A61K9/20H6H:	. . . . Proteins, e.g. gelatin
A61K9/20H8:	. . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/20H4
A61K9/20K:	. . characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms A61K9/00L4, A61K9/00M18B, A61K9/00M18F take precedence
A61K9/20K2:	. . . Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
A61K9/20K2B:	. . . . with microcapsules or coated microparticles according to A61K9/50
A61K9/20K4:	. . . Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
A61K9/20K4B:	. . . . containing drug in at least two layers or in the core and in at least one outer layer
A61K9/20P:	. . Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing mechanical aspects A61J3/00
A61K9/28:	. . Dragees; Coated pills or tablets e.g. with film or compression coating A61K9/20K takes precedence, e.g. partially coated tablets A61K9/20K, coated multilayer tablets A61K9/20K4, tablets with drug-coated core A61K9/20K4B
A61K9/28H:	. . . Coating materials
A61K9/28H2:	. . . . Inorganic compounds
A61K9/28H4:	. . . . Organic compounds, e.g. fats
A61K9/28H4B:	. . . . . Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
A61K9/28H6:	. . . . Organic macromolecular compounds
A61K9/28H6B:	. . . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
A61K9/28H6B2:	. . . . . . Poly(meth)acrylates
A61K9/28H6D:	. . . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
A61K9/28H6F:	. . . . . Polysaccharides, e.g. gums; Cyclodextrin
A61K9/28H6F2:	. . . . . . Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
A61K9/28H6H:	. . . . . Proteins, e.g. gelatin
A61K9/28H8:	. . . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/28H4
A61K9/28K:	. . . having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/20K4B
A61K9/28P:	. . . Tablet coating processes mechanical aspects A61J3/06
A61K9/48:	. Preparations in capsules, e.g. of gelatin, of chocolate; A61K9/00L4 takes precedence; bite capsules A61K9/00M18B
A61K9/48A:	. . characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, coated microparticles A61K9/50M
A61K9/48B:	. . Wall or shell material
A61K9/48B1:	. . . Proteins, e.g. gelatin gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/48B
A61K9/48C:	. . Encapsulating processes; Filling of capsules mechanical aspects A61J3/07
A61K9/48H:	. . Filling excipients; Inactive ingredients
A61K9/48H2:	. . . Inorganic compounds
A61K9/48H4:	. . . Organic compounds
A61K9/48H6:	. . . Organic macromolecular compounds
A61K9/48H8:	. . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/48H4
A61K9/48P:	. . Capsule finishing, e.g. dyeing, aromatising, polishing
A61K9/48Z:	. . Coated capsules; Multilayered drug free capsule shells with drug coating for immediate release A61K9/48A; osmotic devices A61K9/00L4
A61K9/50:	. . Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals A61K9/20K2B takes precedence; particles with a single coating comprising drug A61K9/16K
A61K9/50H:	. . . Wall or coating material
A61K9/50H2:	. . . . Inorganic compounds
A61K9/50H4:	. . . . Organic compounds, e.g. fats, sugars
A61K9/50H6:	. . . . Organic macromolecular compounds
A61K9/50H6B:	. . . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K9/50H6D:	. . . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
A61K9/50H6F:	. . . . . Polysaccharides, e.g. gums, alginate; Cyclodextrin
A61K9/50H6F2:	. . . . . . Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
A61K9/50H6F2B:	. . . . . . . Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
A61K9/50H6H:	. . . . . Proteins, e.g. albumin
A61K9/50H6H2:	. . . . . . Gelatin
A61K9/50H8:	. . . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/50H4
A61K9/50H8B:	. . . . . Cell membranes or bacterial membranes enclosing drugs with additional exogenous lipids A61K9/127; virus envelopes A61K9/51H8B
A61K9/50K:	. . . having two or more different coatings optionally including drug-containing subcoatings
A61K9/50K2:	. . . . with drug-free core
A61K9/50M:	. . . Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/20K2
A61K9/50P:	. . . Processes
A61K9/50T:	. . . Microcapsules containing magnetic carrier material, e.g. ferrite for drug targetting
A61K9/51:	. . . Nanocapsules; Nanoparticles;nanotubes A61K9/00Z4; polymeric micelles A61K9/107D; polymersomes A61K9/127B4; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/14H; conjugates, e.g. between drug and non-active nanoparticles, A61K47/48; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
A61K9/51H:	. . . . Excipients; Inactive ingredients
A61K9/51H2:	. . . . . Inorganic compounds
A61K9/51H4:	. . . . . Organic compounds, e.g. fats, sugars
A61K9/51H6:	. . . . . Organic macromolecular compounds; Dendrimers
A61K9/51H6B:	. . . . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
A61K9/51H6D:	. . . . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
A61K9/51H6D4:	. . . . . . . Polyesters, e.g. poly(lactide-co-glycolide)
A61K9/51H6F:	. . . . . . Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
A61K9/51H6H:	. . . . . . Proteins, e.g. albumin, gelatin
A61K9/51H8:	. . . . . Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/51H4
A61K9/51H8B:	. . . . . . Virus capsids or envelopes enclosing drugs with additional exogenous lipids A61K9/127; bacterial membranes A61K9/50H8B
A61K9/51P:	. . . . Processes
A61K9/70:	. Web, sheet or filament bases; Films; Fibres of the matrix type containing drug; hollow drug-filled fibres A61K9/00Z4; bandages, dressings or absorbent pads A61F13/00, chemical aspects thereof A61L15/00
A61K9/70B:	. . [N: Drug-containing films, membranes or sheets ]
A61K9/70D:	. . Drug-containing film-forming compositions, e.g. spray-on
A61K9/70E:	. . Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/00L8; microneedle arrays A61K9/00M5B; buccal patches A61K9/00M18D
A61K9/70E2:	. . . characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
A61K9/70E2B:	. . . . Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
A61K9/70E2B6:	. . . . . the adhesive comprising macromolecular compounds
A61K9/70E2B6B:	. . . . . . obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
A61K9/70E2B6B2:	. . . . . . . Polyacrylates
A61K9/70E2B6D:	. . . . . . obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
A61K9/70E2B8:	. . . . . the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
A61K9/70E2D:	. . . . Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
A61K9/70E2K:	. . . . Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
A61K31/00:	Medicinal preparations containing organic active ingredients
A61K31/01:	. Hydrocarbons
A61K31/13P:	. . Primary amines[N9509]
A61K31/015:	. . carbocyclic
A61K31/02:	. Halogenated hydrocarbons
A61K31/025:	. . carbocyclic
A61K31/03:	. . . aromatic
A61K31/035:	. . having aliphatic unsaturation
A61K31/04:	. Nitro compounds
A61K31/045:	. Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A61K31/047:	. . having two or more hydroxy groups, e.g. sorbitol
A61K31/05:	. . Phenols
A61K31/055:	. . . the aromatic ring being substituted by halogen
A61K31/06:	. . . the aromatic ring being substituted by nitro groups
A61K31/065:	. . Diphenyl-substituted acyclic alcohols
A61K31/07:	. . Retinol compounds, e.g. vitamin A
A61K31/71:	. . . dummy
A61K31/075:	. Ethers or acetals
A61K31/08:	. . acyclic, e.g. paraformaldehyde
A61K31/085:	. . having an ether linkage to aromatic ring nuclear carbon
A61K31/09:	. . . having two or more such linkages
A61K31/095:	. Sulfur, selenium, or tellurium compounds, e.g. thiols
A61K31/10:	. . Sulfides; Sulfoxides ; Sulfones
A61K31/105:	. . Persulfides
A61K31/11:	. Aldehydes
A61K31/115:	. . Formaldehyde
A61K31/12:	. Ketones
A61K31/121:	. . acyclic
A61K31/122:	. . having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K31/125:	. . . Camphor; Nuclear substituted derivatives thereof
A61K31/13:	. Amines A61K31/04 takes precedence
A61K31/131:	. . acylic
A61K31/132:	. . having two or more amino groups, e.g. spermidine, putrescine
A61K31/133:	. . having hydroxy groups, e.g. sphingosine
A61K31/135:	. . having aromatic rings e.g. ketamine, nortriptyline methadone A61K31/137
A61K31/136:	. . . having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K31/137:	. . . Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
A61K31/138:	. . . Aryloxyalkylamines, e.g. propanolol, tamoxifen, phenoxybenzamine
A61K31/14:	. . Quaternary ammonium compounds, e.g. edrophonium, choline [M1204]
A61K31/145:	. . having sulfur, e.g. thiurams
A61K31/15:	. . N-N=) Imines (C-N=C)
A61K31/155:	. . Amidines (-N=C-N-), e.g. guanidine (H2N-C(=NH)-NH2), isourea (N=C(OH)-NH2), isothiourea (-N=C(SH)-NH2)[M1204]
A61K31/16:	. Amides, e.g. hydroxamic acids
A61K31/164:	. . of a carboxlic acid with an aminoalcohol, e.g. ceramides
A61K31/165:	. . having aromatic rings, e.g. colchicine, atenolol, progabide
A61K31/166:	. . . having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol [M1204]
A61K31/167:	. . . having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol [M1204]
A61K31/17:	. . N-C [M1204]
A61K31/175:	. . . N-C(O)-N=N- or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
A61K31/18:	. . Sulfonamides
A61K31/185:	. Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
A61K31/19:	. . Carboxylic acids, e.g. valproic acid
A61K31/191:	. . . having two or more hydroxy groups, e.g. gluconic acid
A61K31/192:	. . . having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid [M1204]
A61K31/194:	. . . having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K31/195:	. . . having an amino group
A61K31/196:	. . . . the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K31/197:	. . . . the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [M1204]
A61K31/198:	. . . . . Alpha-aminoacids, e.g. alanine, edetic acids [M1204]
A61K31/20:	. . . having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K31/201:	. . . . having one or two double bonds, e.g. oleic, linoleic acids [M1204]
A61K31/202:	. . . . having three or more double bonds, e.g. linolenic
A61K31/203:	. . . . Retinoic acids Salts thereof
A61K31/205:	. . Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
A61K31/21:	. Esters, e.g. nitroglycerine, selenocyanates
A61K31/215:	. . of carboxylic acids
A61K31/216:	. . . of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K31/22:	. . . of acyclic acids, e.g. pravastatin
A61K31/221:	. . . . with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K31/222:	. . . . with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K31/223:	. . . . of alpha-aminoacids
A61K31/225:	. . . . Polycarboxylic acids
A61K31/23:	. . . . of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K31/231:	. . . . . having one or two double bonds
A61K31/232:	. . . . . having three or more double bonds, e.g. etretinate
A61K31/235:	. . . having an aromatic ring attached to a carboxyl group
A61K31/24:	. . . . having an amino or nitro group
A61K31/245:	. . . . . Amino benzoic acid types, e.g. procaine, novocaine [M1204]
A61K31/25:	. . . with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
A61K31/255:	. . of sulfoxy acids or sulfur analogues thereof
A61K31/26:	. . Cyanate or isoyanate esters; Thiocyanate or isothiocyanate esters
A61K31/265:	. . of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K31/27:	. . of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K31/275:	. Nitriles; Isonitriles
A61K31/277:	. . having a ring, e.g. verapamil
A61K31/28:	. Compounds containing heavy metals
A61K31/282:	. . Platinum compounds
A61K31/285:	. . Arsenic compounds
A61K31/29:	. . Antimony or bismuth compounds
A61K31/295:	. . Iron group metal compounds
A61K31/30:	. . Copper compounds
A61K31/305:	. . Mercury compounds
A61K31/31:	. . . containing nitrogen
A61K31/315:	. . Zinc compounds
A61K31/32:	. . Tin compounds
A61K31/325:	. Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
A61K31/327:	. Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
A61K31/33:	. Heterocyclic compounds
A61K31/335:	. . having oxygen as the only ring hetero atom, e.g. fungichromin
A61K31/336:	. . . having three-membered rings, e.g. oxirane, fumagillin
A61K31/337:	. . . having four-membered rings, e.g. taxol
A61K31/34:	. . . having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K31/341:	. . . . not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K31/343:	. . . . condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K31/345:	. . . . Nitrofurans
A61K31/35:	. . . having six-membered rings with one oxygen as the only ring hetero atom
A61K31/351:	. . . . not condensed with another ring
A61K31/352:	. . . . condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K31/353:	. . . . . 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K31/355:	. . . . . . Tocopherols, e.g. vitamin E
A61K31/357:	. . . having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K31/36:	. . . Compounds containing methylenedioxyphenyl groups, e.g. sesamin [M1204]
A61K31/365:	. . . Lactones
A61K31/366:	. . . . having six-membered rings, e.g. delta-lactones
A61K31/37:	. . . . . Coumarins, e.g. psoralen [M1204]
A61K31/375:	. . . . Ascorbic acid, i.e. vitamin C; Salts thereof
A61K31/38:	. . having sulfur as a ring hetero atom
A61K31/381:	. . . having five-membered rings
A61K31/382:	. . . having six-membered rings, e.g. thioxanthenes
A61K31/385:	. . . having two or more sulfur atoms in the same ring
A61K31/39:	. . . having oxygen in the same ring
A61K31/395:	. . having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
A61K31/396:	. . . having thre-membered rings, e.g. aziridine
A61K31/397:	. . . having four-membered rings, e.g. azetidine
A61K31/40:	. . . having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K31/401:	. . . . Proline; Derivatives thereof, e.g. captopril
A61K31/4015:	. . . . having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide [M1204]
A61K31/402:	. . . . 1-aryl substituted, e.g. piretanide
A61K31/4025:	. . . . not condensed and containing further heterocyclic rings, e.g. cromakalim [M1204]
A61K31/403:	. . . . condensed with carbocyclic rings, e.g. carbazole
A61K31/4035:	. . . . . Isoindoles, e.g. phthalimide
A61K31/404:	. . . . . Indoles, e.g. pindolol
A61K31/4045:	. . . . . . Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K31/405:	. . . . . . Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin [M1204]
A61K31/407:	. . . . condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K31/409:	. . . . having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine [M1204]
A61K31/41:	. . . having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/415:	. . . . 1,2-Diazoles
A61K31/4152:	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone [M1204]
A61K31/4155:	. . . . . non condensed and containing further heterocyclic rings
A61K31/416:	. . . . . condensed with carbocyclic ring systems, e.g. indazole
A61K31/4162:	. . . . . condensed with heterocyclic ring systems [M1204]
A61K31/4164:	. . . . 1,3-Diazoles
A61K31/4166:	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin [M1204]
A61K31/4168:	. . . . . having a nitrogen attached in position 2, e.g. clonidine
A61K31/417:	. . . . . Imidazole-alkylamines, e.g. histamine, phentolamine
A61K31/4172:	. . . . . Imidazole-alkanecarboxylic acids, e.g. histidine
A61K31/4174:	. . . . . Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K31/4178:	. . . . . not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K31/4184:	. . . . . condensed with carbocyclic rings, e.g. benzimidazoles
A61K31/4188:	. . . . . condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K31/4192:	. . . . 1,2,3-Triazoles [M1204]
A61K31/4196:	. . . . 1,2,4-Triazoles [M1204]
A61K31/42:	. . . . Oxazoles
A61K31/421:	. . . . . 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K31/422:	. . . . . not condensed and containing further heterocyclic rings
A61K31/423:	. . . . . condensed with carbocyclic rings
A61K31/424:	. . . . . condensed with heterocyclic ring systems, e.g. clavulanic acid
A61K31/4245:	. . . . Oxadiazoles [M1204]
A61K31/425:	. . . . Thiazoles
A61K31/426:	. . . . . 1,3-Thiazoles
A61K31/427:	. . . . . not condensed and containing further heterocyclic rings
A61K31/428:	. . . . . condensed with carbocyclic rings
A61K31/429:	. . . . . condensed with heterocyclic ring systems
A61K31/43:	. . . . . . Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula e.g. penicillins, penems [M1204]
A61K31/431:	. . . . . . . containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
A61K31/433:	. . . . Thidiazoles
A61K31/435:	. . . having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/4353:	. . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/4355:	. . . . . the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K31/436:	. . . . . the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e..g. rapamycin
A61K31/4365:	. . . . . the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine [M1204]
A61K31/437:	. . . . . the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K31/4375:	. . . . . the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine [M1204]
A61K31/438:	. . . . the ring being spiro-condensed with carbocyclic ring systems
A61K31/439:	. . . . the ring forming part of a bridged ring system, e.g. quinuclidine [M1204]
A61K31/44:	. . . . Non condensed pyridines; Hydrogenated derivatives thereof
A61K31/4402:	. . . . . only substituted in position 2, e.g. pheniramine, bisacodyl
A61K31/4406:	. . . . . only substituted in position 3, e.g. zimeldine
A61K31/4409:	. . . . . only substituted in position 4, e.g. isoniazid, iproniazid [M1204]
A61K31/4412:	. . . . . having oxo groups directly attached to the heterocyclic ring
A61K31/4415:	. . . . . Pyridoxine, i.e. Vitamin B6
A61K31/4418:	. . . . . having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K31/4422:	. . . . . 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
A61K31/4425:	. . . . . Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
A61K31/4427:	. . . . . containing further heterocyclic ring systems
A61K31/443:	. . . . . . containing a five-membered ring with oxygen as a ring hetero atom
A61K31/4433:	. . . . . . containing a six-membered ring with oxygen as a ring hetero atom
A61K31/4436:	. . . . . . containing a heterocyclic ring having sulfur as a ring hetero atom
A61K31/4439:	. . . . . . containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K31/444:	. . . . . . containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K31/445:	. . . . . Non condensed piperidines, e.g. piperocaine
A61K31/4453:	. . . . . . only substituted in position 1, e.g. propipocaine, diperodon
A61K31/4458:	. . . . . . only substituted in position 2, e.g. methylphenidate
A61K31/4462:	. . . . . . only substituted in position 3
A61K31/4465:	. . . . . . only substituted in position 4
A61K31/4468:	. . . . . . having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
A61K31/45:	. . . . . . having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K31/451:	. . . . . . having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K31/4515:	. . . . . . having a butyrophenone group in position 1, e.g. haloperidol
A61K31/452:	. . . . . . Piperidinium derivatives
A61K31/4523:	. . . . . . containing further heterocyclic ring systems
A61K31/4525:	. . . . . . . containing a five-membered ring with oxygen as a ring hetero atom
A61K31/453:	. . . . . . . containing a six-membered ring with oxygen as a ring hetero atom
A61K31/4535:	. . . . . . . containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K31/454:	. . . . . . . containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K31/4545:	. . . . . . . containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K31/455:	. . . . . Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
A61K31/46:	. . . . 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine [M1204]
A61K31/465:	. . . . Nicotine; Derivatives thereof
A61K31/47:	. . . . Quinolines; Isoquinolines
A61K31/4704:	. . . . . 2-Quinolinones, e.g. carbostyril
A61K31/4706:	. . . . . 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K31/4709:	. . . . . Non-condensed quinolines and containing further heterocyclic rings
A61K31/472:	. . . . . Non-condensed isoquinolines, e.g. papaverine
A61K31/4725:	. . . . . . containing further heterocyclic rings [M1204]
A61K31/473:	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines [M1204]
A61K31/4738:	. . . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/4741:	. . . . . . condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K31/4743:	. . . . . . condensed with ring systems having sulfur as a ring hetero atom
A61K31/4745:	. . . . . . condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines [M1204]
A61K31/4747:	. . . . . Spiro-condensed
A61K31/4748:	. . . . . forming part of bridged ring systems
A61K31/475:	. . . . . having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine [M1204]
A61K31/48:	. . . . . Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K31/485:	. . . . . Morphinan derivatives, e.g. morphine, codeine
A61K31/49:	. . . . . Cinchonan derivatives, e.g. quinine
A61K31/495:	. . . having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines with three nitrogen atoms A61K31/53
A61K31/496:	. . . . Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K31/4965:	. . . . Non-condensed pyrazines
A61K31/497:	. . . . . containing further heterocyclic rings
A61K31/498:	. . . . Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K31/4985:	. . . . Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K31/499:	. . . . Spiro-condensed pyrazines or piperazines
A61K31/4995:	. . . . Pyrazines or piperazines forming part of bridged ring systems
A61K31/50:	. . . . Pyridazines; Hydrogenated pyridazines
A61K31/501:	. . . . . not condensed and containing further heterocyclic rings
A61K31/502:	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K31/5025:	. . . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/503:	. . . . . spiro-condensed
A61K31/504:	. . . . . forming part of bridged ring systems
A61K31/505:	. . . . Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K31/506:	. . . . . not condensed and containing further heterocyclic rings
A61K31/51:	. . . . . . Thiamines, e.g. vitamin B1
A61K31/513:	. . . . . having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [M1204]
A61K31/515:	. . . . . Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
A61K31/517:	. . . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K31/519:	. . . . . ortho- or peri-condensed with heterocyclic rings
A61K31/52:	. . . . . . Purines, e.g. adenine
A61K31/522:	. . . . . . . having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir [M1204]
A61K31/525:	. . . . . . Isoalloxazines, e.g. riboflavins, vitamin B2
A61K31/527:	. . . . . spiro-condensed
A61K31/529:	. . . . . forming part of bridged ring systems
A61K31/53:	. . . having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine, with four nitrogen atoms A61K31/495
A61K31/535:	. . . having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K31/5355:	. . . . non-condensed oxazines and containing further heterocyclic rings
A61K31/536:	. . . . ortho- or peri-condensed with carbocyclic ring systems
A61K31/5365:	. . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/537:	. . . . spiro-condensed or forming part of bridged ring systems
A61K31/5375:	. . . . 1,4-Oxazines, e.g. morpholine [M1204]
A61K31/5377:	. . . . . not condensed and containing further heterocyclic rings, e.g. timolol [M1204]
A61K31/538:	. . . . . ortho- or peri-condensed with carbocyclic ring systems
A61K31/5383:	. . . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/5386:	. . . . . Spiro-condensed or forming part of bridged ring systems
A61K31/539:	. . . . having two or more oxygen atoms in the same ring, e.g. dioxazines
A61K31/5395:	. . . . having two or more nitrogen atoms in the same ring, e.g. oxadiazines
A61K31/54:	. . . having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
A61K31/541:	. . . . non-condensed thiazines containing further heterocyclic rings [M1204]
A61K31/5415:	. . . . ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K31/542:	. . . . ortho- or peri-condensed with heterocyclic ring systems
A61K31/545:	. . . . . Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine [M1204]
A61K31/546:	. . . . . . containing further heterocyclic rings, e.g. cephalothin
A61K31/547:	. . . . spiro-condensed or forming part of bridged ring systems
A61K31/548:	. . . . having two or more sulfur atoms in the same ring
A61K31/549:	. . . . having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K31/55:	. . . having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K31/551:	. . . . having two nitrogen atoms, e.g. dilazep [M1204]
A61K31/5513:	. . . . . 1,4-Benzodiazepines, e.g. diazepam or clozapine [M1204]
A61K31/5517:	. . . . . . condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K31/553:	. . . . having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K31/554:	. . . . having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem [M1204]
A61K31/555:	. . containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K31/557:	. Eicosanoids, e.g. leukotrienes or prostaglandins [M1204]
A61K31/5575:	. . having a cyclopentane, e.g. Prostaglandin E2, Prostaglandin F2-alpha [M1204]
A61K31/5578:	. . having a pentalene ring system, e.g. carbacyclin, iloprost
A61K31/558:	. . having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
A61K31/5585:	. . . having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K31/559:	. . having heterocyclic rings containing hetero atoms other than oxygen
A61K31/56:	. Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61K31/565:	. . not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
A61K31/566:	. . . having an oxo group in position 17, e.g. estrone [M1204]
A61K31/567:	. . . substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K31/568:	. . . substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
A61K31/5685:	. . . . having an oxo group in position 17, e.g. androsterone [M1204]
A61K31/569:	. . . . substituted in position 17 alpha, e.g. ethisterone
A61K31/57:	. . substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61K31/573:	. . . substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone [M1204]
A61K31/575:	. . substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K31/58:	. . containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
A61K31/585:	. . . containing lactone rings, e.g. oxandrolone, bufalin
A61K31/59:	. Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
A61K31/592:	. . 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
A61K31/593:	. . 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
A61K31/60:	. Salicylic acid; Derivatives thereof
A61K31/603:	. . having further aromatic rings, e.g. diflunisal
A61K31/606:	. . having amino groups
A61K31/609:	. . Amides, e.g. salicylamide labetalol, metoclopramide A61K31/166 [M1204]
A61K31/612:	. . having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
A61K31/616:	. . . by carboxylic acids, e.g. acetylsalicyclic acid
A61K31/618:	. . having the carboxyl group in position 1 esterified, e.g. salsalate
A61K31/621:	. . . having the hydroxy group in position 2 esterified, e.g. benorylate
A61K31/625:	. . having heterocyclic substituents, e.g. 4-salicycloylmorpholine,
A61K31/63:	. Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
A61K31/635:	. . having a heterocyclic ring, e.g. sulfasalazine
A61K31/64:	. Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K31/65:	. Tetracyclines
A61K31/655:	. N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds [M1204]
A61K31/66:	. Phosphorus compounds
A61K31/661:	. . Phosphorus acids or esters thereof not having P-C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos [M1204]
A61K31/6615:	. . . Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [M1204]
A61K31/662:	. . Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
A61K31/663:	. . . Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K31/664:	. . Amides of phosphorus acids
A61K31/665:	. . having oxygen as a ring hetero atom, e.g. fosfomycin
A61K31/67:	. . having sulfur as a ring hetero atom
A61K31/675:	. . having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K31/683:	. . Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K31/685:	. . . one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K31/688:	. . . both hydroxy compounds having nitrogen atoms, e.g. sphingomyelin
A61K31/69:	. Boron compounds
A61K31/695:	. Silicon compounds
A61K31/70:	. Carbohydrates; Sugars; Derivatives thereof
A61K31/7004:	. . Monosaccharide having only carbon, hydrogen and oxygen atoms
A61K31/7008:	. . Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61K31/7012:	. . Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid [M1204]
A61K31/7016:	. . Disaccharides, e.g. lactose, lactulose
A61K31/702:	. . Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K31/7024:	. . Esters of saccharides
A61K31/7028:	. . Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K31/7032:	. . . attached to a polyol, i.e. compound having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides [M1204]
A61K31/7034:	. . . attached to a carbocyclic compound, e.g. phloridzin
A61K31/7036:	. . . . having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins [M1204]
A61K31/704:	. . . . attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048 [M1204]
A61K31/7042:	. . Compounds having saccharide radicals and heterocyclic rings
A61K31/7048:	. . . having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
A61K31/7052:	. . . having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K31/7056:	. . . . containing five-membered rings with nitrogen as a ring hetero atom
A61K31/706:	. . . . containing six-membered rings with nitrogen as a ring hetero atom
A61K31/7064:	. . . . . containing condensed or non-condensed pyrimidines
A61K31/7068:	. . . . . . having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K31/7072:	. . . . . . . having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K31/7076:	. . . . . . containing purines, e.g. adenosine, adenylic acid
A61K31/708:	. . . . . . . having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
A61K31/7084:	. . Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K31/7088:	. . Compounds having three or more nucleosides or nucleotides
A61K31/7105:	. . . Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K31/711:	. . . Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K31/7115:	. . . Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K31/712:	. . . Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K31/7125:	. . . Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K31/713:	. . . Double-stranded nucleic acids or oligonucleotides
A61K31/7135:	. . Compounds containing heavy metals
A61K31/714:	. . . Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
A61K31/715:	. . Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61K31/716:	. . . Glucans
A61K31/717:	. . . . Celluloses
A61K31/718:	. . . . Starch or degraded starch, e.g. amylose, amylopectin
A61K31/719:	. . . . Pullulans [M1204]
A61K31/721:	. . . . Dextrans
A61K31/722:	. . . . Chitin, chitosan
A61K31/723:	. . . . Xanthans
A61K31/724:	. . . . Cyclodextrins
A61K31/726:	. . . Glycosaminoglycans, i.e. mucopolysaccharides
A61K31/727:	. . . . Heparin; Heparan
A61K31/728:	. . . . Hyaluronic acid
A61K31/729:	. . . Agar; Agarose; Agaropectin
A61K31/731:	. . . Carrageenans
A61K31/732:	. . . Pectin
A61K31/733:	. . . Fructosans, e.g. inulin
A61K31/734:	. . . Alginic acid
A61K31/736:	. . . Glucomannans or galactomannans, e.g. locust bean gum, guar gum
A61K31/737:	. . . Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate [M1204]
A61K31/738:	. . . Cross-linked polysaccharides
A61K31/739:	. . . Lipopolysaccharides
A61K31/74:	. Synthetic polymeric materials
A61K31/745:	. . Polymers of hydrocarbons
A61K31/75:	. . . of ethene
A61K31/755:	. . Polymers containing halogen
A61K31/76:	. . . of vinyl chloride
A61K31/765:	. . Polymers containing oxygen
A61K31/77:	. . . of oxiranes
A61K31/775:	. . . Phenolic resins
A61K31/78:	. . . of acrylic acid or derivatives thereof
A61K31/785:	. . Polymers containing nitrogen
A61K31/787:	. . . containing heterocyclic rings having nitrogen as a ring hetero atom
A61K31/79:	. . . . Polymers of vinyl pyrrolidone
A61K31/795:	. . Polymers containing sulfur
A61K31/80:	. . Polymers containing hetero atoms not provided for in groups A61K31/755 to A61K31/795
A61K33/00:	Medicinal preparations containing inorganic active ingredients
A61K33/02:	. Ammonia; Compounds thereof
A61K33/04:	. Sulfur, selenium or tellurium; Compounds thereof
A61K33/06:	. Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
A61K33/08:	. . Oxides; Hydroxides
A61K33/10:	. . Carbonates; Bicarbonates
A61K33/12:	. . Magnesium silicate
A61K33/14:	. Alkali metal chlorides; Alkaline earth metal chlorides
A61K33/16:	. Fluorine compounds
A61K33/18:	. Iodine; Compounds thereof
A61K33/20:	. Elemental chlorine; Inorganic compounds releasing chlorine
A61K33/22:	. Boron compounds
A61K33/24:	. Heavy metals; Compounds thereof
A61K33/24B:	. . Bismuth; Derivatives thereof
A61K33/26:	. . Iron; Compounds thereof
A61K33/28:	. . Mercury; Compounds thereof
A61K33/30:	. . Zinc; Compounds thereof
A61K33/32:	. . Manganese; Compounds thereof
A61K33/34:	. . Copper; Compounds thereof
A61K33/36:	. . Arsenic; Compounds thereof
A61K33/38:	. . Silver; Compounds thereof
A61K33/40:	. Peroxides
A61K33/42:	. Phosphorus; Compounds thereof
A61K33/44:	. Elemental carbon, e.g. charcoal, carbon black
A61K35/00:	Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K35/02:	. from inanimate materials
A61K35/04:	. . Tars; Bitumens; Mineral oils; Ammonium bituminisulfonates, e.g. ichthyol
A61K35/06:	. . . Mineral oils, e.g. paraffinic oils, aromatic oils based on aromatic hydrocarbons essential oils derived from plants A61K36/00
A61K35/78:	. Materials from plants [N: (antigens from pollen A61K39/36)]
A61K35/08:	. . Mineral waters; Sea water
A61K35/80:	. . Algae
A61K35/82:	. . Lichens
A61K35/84:	. . Higher fungi
A61K35/10:	. . Peat; Amber; Turf; Humus wood tar, sap or resin A61K36/00
A61K35/12:	. Materials from mammals; compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells uncharacterized stem cells A61K35/54A; Genetically modified cells (gene therapy C12N5/10; vaccines or medicinal preparations containing antigens or antibodies A61K39/00 Note: If the cells are characterized, classify under the corresponding tissue or tissue of origin
A61K35/13:	. . Tumor cells, irrespective of tissue of origin tumor vaccines A61K39/00
A61K35/14:	. . Blood haemoglobin A61K38/42; umbilical cord blood A61K35/51 ; Artificial blood ]
A61K35/15:	. . . Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen presenting cells, e.g. dendritic cells presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K35/15, A61K39/00 or C07K16/00
A61K35/16:	. . . Blood plasma; Blood serum umbilical cord blood A61K35/51
A61K35/17:	. . . Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon- and cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
A61K35/18:	. . . Erythrocytes hemoglobin A61K38/42
A61K35/19:	. . . Platelets; Megacaryocytes
A61K35/20:	. . Milk; Colostrum; Whey
A61K35/22:	. . Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland ; Urine
A61K35/23:	. . . Kidney
A61K35/24:	. . Mucus; Mucous glands; Bursa; Synovial fluid ; Arthral fluid; Excreta; Spinal fluid saliva A61K35/38
A61K35/26:	. . Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
A61K35/28:	. . Bone marrow; Hematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K35/30:	. . Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia, astrocytes; Choroid plexus; Spinal cord tissue
A61K35/32:	. . Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
A61K35/33:	. . Fibroblasts
A61K35/34:	. . Muscles; Smooth muscle cells Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
A61K35/35:	. . Fat tissue; Adipocytes; Stromal cells; Connective tissues of general nature adipose-derived stem cells A61K35/28, collagen A61K38/39
A61K35/36:	. . Skin; Hair; Nails; Sebacious glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ecdodermal cells islets of Langerhans A61K35/39
A61K35/37:	. . Digestive system
A61K35/38:	. . . Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
A61K35/39:	. . . Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
A61K35/407:	. . . Liver; Hepatocytes
A61K35/413:	. . . Gallbladder; Bile
A61K35/42:	. . Respiratory System: e.g. Lungs; Bronchi; Lung cells
A61K35/44:	. . Vessels e.g. blood vessels or lymphatic vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
A61K35/48:	. . Reproductive organs
A61K35/50:	. . . Placenta; Amniotic fluid; Amnion, Amniotic stem cells; Placental stem cells
A61K35/51:	. . . Umbilical cord; Umbilical cord blood; Umbilical stem cells
A61K35/52:	. . . Sperm Prostate, Seminal fluid; Leydig cells of testes
A61K35/54:	. . . Ovary; Embryos; Fetal cells; Germ cells
A61K35/54A:	. . . . Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterized stem cells
A61K35/55:	. . Glands not provided for in any of the preceding subgroups of this main group e.g. thyroid, parathyroid, pineal gland
A61K35/56:	. Materials from animals other than mammals
A61K35/57:	. . Birds; Materials from birds, e.g. eggs or feathers
A61K35/58:	. . Reptiles
A61K35/58A:	. . . Snakes [N: Lizards; Chameleons (therapeutic use of a snake venom protein A61K38)
A61K35/58B:	. . . Turtles, Tortoises
A61K35/60:	. . Fish; Seahorses; Fish eggs
A61K35/61:	. . Sea animals other than those covered by group A61K35/60
A61K35/61A:	. . . Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
A61K35/61B:	. . . Cnidaria, e.g. sea anemones, corals, coral animals, jellyfish
A61K35/61C:	. . . Echinodermata, e.g. star fish, sea cucumbers, sea urchins
A61K35/61D:	. . . Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
A61K35/62:	. . Leeches; Worms, e.g. cestodes or tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
A61K35/64:	. . Arthropods
A61K35/64A:	. . . Insects, e.g. bees, wasps or fleas
A61K35/64A1:	. . . . Beeswax; Propolis; Royal jelly; Honey
A61K35/64B:	. . . arachnids, e.g. spiders, scorpions, ticks or mites
A61K35/64C:	. . . Myriapods, e.g. centipedes or millipedes
A61K35/65:	. . Amphibians, e.g. toads, frogs, salamanders, newts
A61K35/66:	. Micro-organisms or materials thereof ]
A61K35/68:	. . Protozoa e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
A61K35/74:	. . Bacteria therapeutic use of a bacterial protein A61K38/00; bacteria per se or mutant bacteria C12R1/00; bacteria in food, for nutritional purposes A23L1/30M
A61K35/74A:	. . . Probiotics as part of food or functional food A23L1/30M; probiotic yeast, i.e. saccharomyces A61K36/06
A61K35/74A1:	. . . . Spore-forming bacteria, e.g. Bacillus coagulans or Lactobacillus sporogenes
A61K35/74A2:	. . . . Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci, leuconostoc
A61K35/74A2A:	. . . . . Bifidobacteria
A61K35/74A2B:	. . . . . Lactobacilli, e.g. L. acidophilus, L. brevis
A61K35/74B:	. . . Cyanobacteria; Spirulina; Blue-green algae; Blue-green bacteria algae, microalgae or microphytes A61K36/00
A61K35/76:	. . Viruses, Bacteriophages; viruses per se C12N7/00; viral proteins per se C07K14/005; use of virus as a vector C12N15/86; use of virus or part thereof as vaccine A61K39/12; therapeutic use of a viral protein A61K38/16
A61K35/76A:	. . . Adenovirus
A61K35/76B:	. . . Herpes virus
A61K35/76C:	. . . Reovirus; Rotavirus
A61K35/76D:	. . . Rhabdovirus, e.g. vesicular stomatitis virus
A61K35/76E:	. . . Other oncolytic viruses
A61K36/00:	Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines antigens from pollen A61K39/36
A61K36/02:	. Algae
A61K36/03:	. . Phaeophycota or phaeophyta (brown algae), e.g. Fucus
A61K36/04:	. . Rhodophycota or rhodophya (red algae), e.g. Porphyra
A61K36/05:	. . Chlorophycota or chlorophyta (green algae), e.g. Chlorella
A61K36/06:	. Fungi, e.g. yeasts
A61K36/062:	. . Ascomycota
A61K36/064:	. . . Saccharomycetales, e.g. baker's yeast
A61K36/066:	. . . Clavicipitaceae
A61K36/068:	. . . . Cordyceps
A61K36/07:	. . Basidiomycota, e.g. Cryptococcus
A61K36/074:	. . . Ganoderma
A61K36/076:	. . . Poria
A61K36/09:	. Lichens
A61K36/10:	. Bryophyta
A61K36/11:	. Pteridophyta or Filicophyta (ferns)
A61K36/12:	. . Filicopsida or Pteridopsida
A61K36/126:	. . . Drynaria
A61K36/13:	. Coniferophyta (gymnosperms)
A61K36/14:	. . Cupressaceae (Cypress family), e.g. juniper or cypress
A61K36/15:	. . Pinaceae (Pine family), e.g. pine or cedar
A61K36/16:	. Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
A61K36/17:	. Gnetophyta, e.g. Ephedraceae (Mormon-tea tamily)
A61K36/18:	. Magnoliophyta (angiosperms)
A61K36/185:	. . Magnoliopsida (dicotyledons)
A61K36/19:	. . . Acanthaceae (Acanthus family)
A61K36/195:	. . . . Strobilanthes
A61K36/20:	. . . Aceraceae (Maple family)
A61K36/21:	. . . Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
A61K36/22:	. . . Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
A61K36/23:	. . . Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
A61K36/232:	. . . . Angelica
A61K36/233:	. . . . Bupleurum
A61K36/234:	. . . . Cnidium (snowparsley)
A61K36/235:	. . . . Foeniculum (fennel)
A61K36/236:	. . . . Ligusticum (licorice-root)
A61K36/237:	. . . . Notopterygium
A61K36/238:	. . . . Saposhnikovia
A61K36/24:	. . . Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
A61K36/25:	. . . Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
A61K36/254:	. . . . Acanthopanax or Eleutherococcus
A61K36/258:	. . . . Panax (ginseng)
A61K36/26:	. . . Aristolochiaceae (Birthwort family), e.g. heartleaf
A61K36/264:	. . . . Aristolochia (Dutchman's pipe)
A61K36/268:	. . . . Asarum (wild ginger)
A61K36/27:	. . . Asclepiadaceae (Milkweed family), e.g. hoya
A61K36/28:	. . . Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
A61K36/282:	. . . . Artemisia, e.g. wormwood or sagebrush
A61K36/284:	. . . . Atractylodes
A61K36/285:	. . . . Aucklandia
A61K36/286:	. . . . Carthamus (distaff thistle)
A61K36/287:	. . . . Chrysanthemum, e.g. daisy
A61K36/288:	. . . . Taraxacum (dandelion)
A61K36/289:	. . . . Vladimiria
A61K36/29:	. . . Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
A61K36/296:	. . . . Epimedium
A61K36/30:	. . . Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
A61K36/31:	. . . Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
A61K36/315:	. . . . Isatis, e.g. Dyer's woad
A61K36/32:	. . . Burseraceae (Frankincense family)
A61K36/324:	. . . . Boswellia, e.g. frankincense
A61K36/328:	. . . . Commiphora, e.g. mecca myrrh or balm of Gilead
A61K36/33:	. . . Cactaceae (Cactus family), e.g. pricklypear or Cereus
A61K36/34:	. . . Campanulaceae (Bellflower family)
A61K36/342:	. . . . Adenophora
A61K36/344:	. . . . Codonopsis
A61K36/346:	. . . . Platycodon
A61K36/35:	. . . Caprifoliaceae (Honeysuckle family)
A61K36/355:	. . . . Lonicera (honeysuckle)
A61K36/36:	. . . Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
A61K36/37:	. . . Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
A61K36/38:	. . . Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
A61K36/39:	. . . Convolvulaceae (Morning-glory family), e.g. bindweed
A61K36/40:	. . . Cornaceae (Dogwood family)
A61K36/41:	. . . Crassulaceae (Stonecrop family)
A61K36/42:	. . . Cucurbitaceae (Cucumber family)
A61K36/424:	. . . . Gynostemma
A61K36/428:	. . . . Trichosanthes
A61K36/43:	. . . Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
A61K36/44:	. . . Ebenaceae (Ebony family), e.g. persimmon
A61K36/45:	. . . Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
A61K36/46:	. . . Eucommiaceae (Eucommia family), e.g. hardy rubber tree
A61K36/47:	. . . Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
A61K36/48:	. . . Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
A61K36/481:	. . . . Astragalus (milkvetch)
A61K36/482:	. . . . Cassia, e.g. golden shower tree
A61K36/483:	. . . . Gleditsia (locust)
A61K36/484:	. . . . Glycyrrhiza (licorice)
A61K36/485:	. . . . Gueldenstaedtia
A61K36/486:	. . . . Millettia
A61K36/487:	. . . . Psoralea
A61K36/488:	. . . . Pueraria (kudzu)
A61K36/489:	. . . . Sophora, e.g. necklacepod or mamani
A61K36/49:	. . . Fagaceae (Beech family), e.g. oak or chestnut
A61K36/50:	. . . Fumariaceae (Fumitory family), e.g. bleeding heart
A61K36/505:	. . . . Corydalis
A61K36/51:	. . . Gentianaceae (Gentian family)
A61K36/515:	. . . . Gentiana
A61K36/52:	. . . Juglandaceae (Walnut family)
A61K36/53:	. . . Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61K36/532:	. . . . Agastache, e.g. giant hyssop
A61K36/533:	. . . . Leonurus (motherwort)
A61K36/534:	. . . . Mentha (mint)
A61K36/535:	. . . . Perilla (beefsteak plant)
A61K36/536:	. . . . Prunella or Brunella (selfheal)
A61K36/537:	. . . . Salvia (sage)
A61K36/538:	. . . . Schizonepeta
A61K36/539:	. . . . Scutellaria (skullcap)
A61K36/54:	. . . Lauraceae (Laurel family), e.g. cinnamon or sassafras
A61K36/55:	. . . Linaceae (Flax family), e.g. Linum
A61K36/56:	. . . Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
A61K36/57:	. . . Magnoliaceae (Magnolia family)
A61K36/575:	. . . . Magnolia
A61K36/58:	. . . Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
A61K36/59:	. . . Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
A61K36/60:	. . . Moraceae (Mulberry family), e.g. breadfruit or fig
A61K36/605:	. . . . Morus (mulberry)
A61K36/61:	. . . Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
A61K36/62:	. . . Nymphaeaceae (Water-lily family)
A61K36/63:	. . . Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
A61K36/634:	. . . . Forsythia
A61K36/638:	. . . . Ligustrum, e.g. Chinese privet
A61K36/64:	. . . Orobanchaceae (Broom-rape family)
A61K36/65:	. . . Paeoniaceae (Peony family), e.g. Chinese peony
A61K36/66:	. . . Papaveraceae (Poppy family), e.g. bloodroot
A61K36/67:	. . . Piperaceae (Pepper family), e.g. Jamaican pepper or kava
A61K36/68:	. . . Plantaginaceae (Plantain Family)
A61K36/69:	. . . Polygalaceae (Milkwort family)
A61K36/70:	. . . Polygonaceae (Buckwheat family), e.g. spineflower or dock
A61K36/704:	. . . . Polygonum, e.g. knotweed
A61K36/708:	. . . . Rheum (rhubarb)
A61K36/71:	. . . Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
A61K36/714:	. . . . Aconitum (monkshood)
A61K36/716:	. . . . Clematis (leather flower)
A61K36/718:	. . . . Coptis (goldthread)
A61K36/72:	. . . Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
A61K36/725:	. . . . Ziziphus, e.g. jujube
A61K36/73:	. . . Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
A61K36/732:	. . . . Chaenomeles, e.g. flowering quince
A61K36/734:	. . . . Crataegus (hawthorn)
A61K36/736:	. . . . Prunus, e.g. plum, cherry, peach, apricot or almond
A61K36/738:	. . . . Rosa (rose)
A61K36/739:	. . . . Sanguisorba (burnet)
A61K36/74:	. . . Rubiaceae (Madder family)
A61K36/744:	. . . . Gardenia
A61K36/746:	. . . . Morinda
A61K36/748:	. . . . Oldenlandia or Hedyotis
A61K36/75:	. . . Rutaceae (Rue family)
A61K36/752:	. . . . Citrus, e.g. lime, orange or lemon
A61K36/754:	. . . . Evodia
A61K36/756:	. . . . Phellodendron, e.g. corktree
A61K36/758:	. . . . Zanthoxylum, e.g. pricklyash
A61K36/76:	. . . Salicaceae (Willow family), e.g. poplar
A61K36/77:	. . . Sapindaceae (Soapberry family), e.g. lychee or soapberry
A61K36/78:	. . . Saururaceae (Lizard's-tail family)
A61K36/79:	. . . Schisandraceae (Schisandra family)
A61K36/80:	. . . Scrophulariaceae (Figwort family)
A61K36/804:	. . . . Rehmannia
A61K36/808:	. . . . Scrophularia (figwort)
A61K36/81:	. . . Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
A61K36/815:	. . . . Lycium (desert-thorn)
A61K36/82:	. . . Theaceae (Tea family), e.g. camellia
A61K36/83:	. . . Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
A61K36/835:	. . . . Aquilaria
A61K36/84:	. . . Valerianaceae (Valerian family), e.g. valerian
A61K36/85:	. . . Verbenaceae (Verbena family)
A61K36/855:	. . . . Clerodendrum, e.g. glorybower
A61K36/86:	. . . Violaceae (Violet family)
A61K36/87:	. . . Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
A61K36/88:	. . Liliopsida (monocotyledons)
A61K36/882:	. . . Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
A61K36/884:	. . . Alismataceae (Water-plantain family)
A61K36/886:	. . . Aloeaceae (Aloe family), e.g. aloe vera
A61K36/888:	. . . Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
A61K36/8884:	. . . . Arisaema, e.g. Jack in the pulpit
A61K36/8888:	. . . . Pinellia
A61K36/889:	. . . Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
A61K36/8895:	. . . . Calamus, e.g. rattan
A61K36/89:	. . . Cyperaceae (Sedge family)
A61K36/8905:	. . . . Cyperus (flatsedge)
A61K36/894:	. . . Dioscoreaceae (Yam family)
A61K36/8945:	. . . . Dioscorea, e.g. yam, Chinese yam or water yam
A61K36/896:	. . . Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
A61K36/8962:	. . . . Allium, e.g. garden onion, leek, garlic or chives
A61K36/8964:	. . . . Anemarrhena
A61K36/8965:	. . . . Asparagus, e.g. garden asparagus or asparagus fern
A61K36/8966:	. . . . Fritillaria, e.g. checker lily or mission bells
A61K36/8967:	. . . . Lilium, e.g. tiger lily or Easter lily
A61K36/8968:	. . . . Ophiopogon (Lilyturf)
A61K36/8969:	. . . . Polygonatum (Solomon's seal)
A61K36/898:	. . . Orchidaceae (Orchid family)
A61K36/8984:	. . . . Dendrobium
A61K36/8988:	. . . . Gastrodia
A61K36/899:	. . . Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
A61K36/8994:	. . . . Coix (Job's tears)
A61K36/8998:	. . . . Hordeum (barley)
A61K36/90:	. . . Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
A61K36/902:	. . . Sparganiaceae (Bur-reed family)
A61K36/904:	. . . Stemonaceae (Stemona family), e.g. croomia
A61K36/906:	. . . Zingiberaceae (Ginger family)
A61K36/9062:	. . . . Alpinia, e.g. red ginger or galangal
A61K36/9064:	. . . . Amomum, e.g. round cardamom
A61K36/9066:	. . . . Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61K36/9068:	. . . . Zingiber, e.g. garden ginger
A61K38/00:	Medicinal preparations containing peptides
A61K38/00A:	. Enzyme inhibitors protease inhibitors A61K38/55
A61K38/01:	. Hydrolysed proteins; Derivatives thereof
A61K38/01B:	. . from plants
A61K38/01D:	. . from animals
A61K38/01D2:	. . . from connective tissue peptides, e.g. gelatin, collagen
A61K38/01D2C:	. . . . from keratin
A61K38/01D4:	. . . from blood
A61K38/01D6:	. . . from milk
A61K38/02:	. Peptides of undefined number of amino acids; Derivatives thereof
A61K38/03:	. Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
A61K38/04:	. Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K38/04E:	. . Kallidins; Bradykinins; Related peptides
A61K38/04T:	. . Tachykinins, e.g. eledoisins, substance P; Related peptides
A61K38/05:	. . Dipeptides
A61K38/06:	. . Tripeptides
A61K38/06A:	. . . Glutathione
A61K38/06B:	. . . TRH, thyroliberin, thyrotropin releasing hormone
A61K38/07:	. . Tetrapeptides
A61K38/08:	. . Peptides having 5 to 11 amino acids A61K38/04E to A61K38/04T take precedence
A61K38/08A:	. . . Angiotensins [M1112]
A61K38/09:	. . . Luteinising hormone-releasing hormone (LHRH) i.e. Gonadotropin-releasing hormone (GnRH) ; Related peptides [M1108]
A61K38/10:	. . Peptides having 12 to 20 amino acids A61K38/04E to A61K38/04T take precedence
A61K38/10D:	. . . Bombesin; Related peptides
A61K38/11:	. . . Oxytocins; Vasopressins; Related peptides
A61K38/12:	. . Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/04E to A61K38/04T take precedence
A61K38/13:	. . . Cyclosporins
A61K38/14:	. . Peptides containing saccharide radicals; Derivatives thereof e.g. bleomycin, phleomycin, muramylpeptides or vancomycin [M1109]
A61K38/15:	. . Depsipeptides; Derivatives thereof
A61K38/16:	. Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/00A
A61K38/16A:	. . from virus
A61K38/16B:	. . from bacteria
A61K38/16B1:	. . . Streptokinase
A61K38/16C:	. . from plants
A61K38/17:	. . from animals; from humans [N: ]
A61K38/17A:	. . . from vertebrates A61K38/17B takes precedence [M1112]
A61K38/17A1:	. . . . from fish
A61K38/17A2:	. . . . from mammals
A61K38/17A2B:	. . . . . Not used, see subgroup
A61K38/17A2B11:	. . . . . . Complement proteins, e.g. anaphylatoxin, C3a, C5a
A61K38/17A2B14:	. . . . . . Cationic antimicrobial peptides, e.g. defensins
A61K38/17A2B16:	. . . . . . Lectins
A61K38/17A2B17:	. . . . . . Mucins, e.g. human intestinal mucin
A61K38/17A2B18:	. . . . . . Calcium binding proteins, e.g. calmodulin
A61K38/17A2B19:	. . . . . . alpha-Glycoproteins
A61K38/17A2B25:	. . . . . . C-reactive protein
A61K38/17A2B28:	. . . . . . Keratin; Cytokeratin
A61K38/17A2B29:	. . . . . . Bactericidal/permeability-increasing protein (BPI)
A61K38/17A2B3:	. . . . . . Amyloid plaque core protein
A61K38/17A2B30:	. . . . . . Insulin-like growth factor binding protein
A61K38/17A2B32:	. . . . . . p53
A61K38/17A2B33:	. . . . . . Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s) (BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis (IAP), Bcl-2
A61K38/17A2B34:	. . . . . . Tumor specific antigens; Tumor rejection antigen precursors (TRAP), e.g. MAGE
A61K38/17A2B7:	. . . . . . Muscle proteins, e.g. myosin, actin
A61K38/17A2B8:	. . . . . . Plasma globulins, lactoglobulin
A61K38/17B:	. . . from invertebrates
A61K38/17C:	. . . Receptors; Cell surface antigens; Cell surface determinants
A61K38/17C1:	. . . . Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules
A61K38/17C13:	. . . . for growth factors; for growth regulators
A61K38/17C14:	. . . . for cytokines; for lymphokines; for interferons
A61K38/17C15:	. . . . for hormones for neuromediators A61K38/17C5
A61K38/17C2:	. . . . Integrin superfamily
A61K38/17C3:	. . . . Lectin superfamily, e.g. selectins
A61K38/17C4:	. . . . Nuclear receptors, e.g. retinoic acid receptor (RAR), RXR, nuclear orphan receptors
A61K38/17C5:	. . . . for neuromediators, e.g. serotonin receptor, dopamine receptor
A61K38/18:	. . . Growth factors; Growth regulators
A61K38/18A:	. . . . Epidermal growth factor (EGF) urogastrone
A61K38/18B:	. . . . Erythropoietin (EPO)
A61K38/18C:	. . . . Fibroblast growth factor (FGF)
A61K38/18D:	. . . . Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
A61K38/18E:	. . . . Transforming growth factor (TGF)
A61K38/18F:	. . . . Nerve growth factor (NGF); Brain derived neurotrophic factor (BDNF); Ciliary neurotrophic factor (CNTF); Glial derived neurotrophic factor (GDNF); Neurotrophins, e.g. NT-3
A61K38/18G:	. . . . Platelet-derived growth factor (PDGF)
A61K38/18G1:	. . . . . Vascular endothelial growth factor (VEGF)
A61K38/18H:	. . . . Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
A61K38/18J:	. . . . Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
A61K38/18K:	. . . . [Angiogenesic factors; Angiogenin]
A61K38/19:	. . . Cytokines; Lymphokines; Interferons
A61K38/195:	. . . . Chemokines, e.g. RANTES
A61K38/196:	. . . . Thrombopoietin
A61K38/19A:	. . . . Tumor necrosis factors [TNF , e.g. lymphotoxin [LT] i.e. TNF-beta] [M1109]
A61K38/19B:	. . . . Colony stimulating factors [CSF ] [M1109]
A61K38/20:	. . . . Interleukins [IL] [M1109]
A61K38/20A:	. . . . . IL-1
A61K38/20B:	. . . . . IL-2
A61K38/20C:	. . . . . IL-3
A61K38/20D:	. . . . . IL-4
A61K38/20E:	. . . . . IL-5
A61K38/20F:	. . . . . IL-6
A61K38/20G:	. . . . . IL-7
A61K38/20H:	. . . . . IL-8
A61K38/20J:	. . . . . IL-9
A61K38/20K:	. . . . . IL-10
A61K38/20L:	. . . . . IL-11
A61K38/20M:	. . . . . IL-12
A61K38/20N:	. . . . . IL-13 to IL-16
A61K38/20T:	. . . . . Leukaemia inhibitory factor (LIF)
A61K38/21:	. . . . Interferons (IFN)
A61K38/21A:	. . . . . IFN-alpha
A61K38/21B:	. . . . . IFN-beta
A61K38/21C:	. . . . . IFN-gamma
A61K38/22:	. . . Hormones
A61K38/22A:	. . . . Gastrins; Cholecystokinins [CCK ] [M1108]
A61K38/22B:	. . . . Motilins
A61K38/22C:	. . . . Relaxins
A61K38/22D:	. . . . Corticotropin releasing factor (CRF) (Urotensin)
A61K38/22E:	. . . . Secretins
A61K38/22F:	. . . . Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein (ANP); Cardionatrin, Cardiodilatin
A61K38/22G:	. . . . Calcitonin gene related peptide
A61K38/22H:	. . . . Prolactin
A61K38/22K:	. . . . Obesity-gene products, e.g. leptin [M1109]
A61K38/22L:	. . . . Neuropeptide Y
A61K38/22M:	. . . . Vasoactive intestinal peptide (VIP); Related peptides (e.g. Exendin)
A61K38/22N:	. . . . Endothelin, vasoactive intestinal contractor (VIC)
A61K38/22P:	. . . . Thymosin; Related peptides
A61K38/23:	. . . . Calcitonins
A61K38/24:	. . . . Follicle-stimulating hormone (FSH); Chorionic gonadotropins, e.g. HCG; Luteinising hormone (LH); Thyroid-stimulating hormone (TSH)
A61K38/25:	. . . . Growth hormone-releasing factor (GH-RF) (Somatoliberin)
A61K38/26:	. . . . Glucagons
A61K38/27:	. . . . Growth hormone (GH) (Somatotropin)
A61K38/28:	. . . . Insulins
A61K38/29:	. . . . Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
A61K38/30:	. . . . Insulin-like growth factors (somatomedins), e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/17A2B30 [M1112]
A61K38/31:	. . . . Somatostatins
A61K38/32:	. . . . Thymopoietins
A61K38/33:	. . . derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
A61K38/34:	. . . . Melanocyte stimulating hormone (MSH), e.g. alpha- or beta-melanotropin
A61K38/35:	. . . . Corticotropin (ACTH)
A61K38/36:	. . . Blood coagulation or fibrinolysis factors
A61K38/36A:	. . . . Fibrinogen
A61K38/36B:	. . . . Thrombomodulin
A61K38/37:	. . . . Factors VIII
A61K38/38:	. . . Albumins
A61K38/38A:	. . . . Serum albumin
A61K38/39:	. . . Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
A61K38/395:	. . . Alveolar surfactant peptides; Pulmonary surfactant peptides
A61K38/40:	. . . Transferrins, e.g. lactoferrins, ovotransferrins
A61K38/41:	. . Porphyrin- or corrin-ring-containing peptides
A61K38/415:	. . . Cytochromes
A61K38/42:	. . . Haemoglobins; Myoglobins
A61K38/43:	. . Enzymes; Proenzymes; Derivatives thereof
A61K38/44:	. . . Oxidoreductases (1)
A61K38/44A:	. . . . acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
A61K38/44B:	. . . . Superoxide dismutase (1.15)
A61K38/45:	. . . Transferases (2)
A61K38/46:	. . . Hydrolases (3)
A61K38/46A:	. . . . acting on ester bonds (3.1), e.g. lipases, ribonucleases
A61K38/47:	. . . . acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K38/48:	. . . . acting on peptide bonds (3.4)
A61K38/48F:	. . . . . from animals other than mammals, e.g. snakes
A61K38/48H:	. . . . . Exopeptidases (3.4.11. to 3.4.19)
A61K38/48K:	. . . . . Serine endopeptidases (3.4.21)
A61K38/48K1:	. . . . . . Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
A61K38/48K21:	. . . . . . Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
A61K38/48K34:	. . . . . . Kallikrein (3.4.21.34 or 3.4.21.35)
A61K38/48K36:	. . . . . . Elastase (3.4.21.36 or 3.4.21.37)
A61K38/48K5:	. . . . . . Thrombin (3.4.21.5)
A61K38/48K69:	. . . . . . Protein C (3.4.21.69)
A61K38/48K7:	. . . . . . Plasmin (3.4.21.7)
A61K38/48L:	. . . . . Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
A61K38/48M:	. . . . . Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
A61K38/48N:	. . . . . Metalloendopeptidases (3.4.24), e.g. collagenase
A61K38/48N1:	. . . . . . Botulinum neurotoxin (3.4.24.69)
A61K38/49:	. . . . . Urokinase; Tissue plasminogen activator
A61K38/50:	. . . . acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
A61K38/51:	. . . Lyases (4)
A61K38/52:	. . . Isomerases (5)
A61K38/53:	. . . Ligases (6)
A61K38/54:	. . . Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 to A61K38/46 or A61K38/51 to A61K38/53
A61K38/55:	. . Protease inhibitors
A61K38/55A:	. . . Renin inhibitors
A61K38/55B:	. . . Angiotensin converting enzyme inhibitors
A61K38/56:	. . . from plants
A61K38/57:	. . . from animals; from humans A61K38/55A, A61K38/55B take precedence
A61K38/58:	. . . . from leeches, e.g. hirudin, eglin
A61K39/00:	Medicinal preparations containing antigens or antibodies
A61K39/002:	. Protozoa antigens
A61K39/005:	. . Trypanosoma antigens
A61K39/008:	. . Leishmania antigens
A61K39/00A:	. Archaeal antigens
A61K39/00B:	. Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
A61K39/00C:	. Invertebrate antigens
A61K39/00D:	. Vertebrate antigens from snakes A61K39/38
A61K39/00D2:	. . Contraceptive vaccins; Vaccines against sex hormones
A61K39/00D3:	. . Nervous system antigens; Prions
A61K39/00D4:	. . Antigens related to auto-immune diseases; Preparations to induce self-tolerance
A61K39/00D5:	. . Preparations to induce tolerance to non-self, e.g. prior to transplantation
A61K39/00D6:	. . Cancer antigens
A61K39/00D8:	. . Lipids; Lipoproteins
A61K39/00E:	. Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
A61K39/00M:	. [N: Combination vaccines based on measles-mumps-rubella ]
A61K39/00P:	. [N: Combination vaccines based on diphtheria-tetanus-pertussis ]
A61K39/00P1:	. . [N: Combination vaccines based on whole cell diphtheria-tetanus-pertussis ]
A61K39/00P2:	. . [N: Combination vaccines based on acellular diphtheria-tetanus-pertussis ]
A61K39/012:	. . Coccidia antigens
A61K39/015:	. . Hemosporidia antigens, e.g. Plasmodium antigens
A61K39/018:	. . . Babesia antigens, e.g. Theileria antigens
A61K39/02:	. Bacterial antigens
A61K39/02A:	. . Specific bacteria not otherwise provided for
A61K39/02C:	. . Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
A61K39/02D:	. . Spirochetes, e.g. Treponema, Leptospira, Borrelia
A61K39/02E:	. . Rickettsiales, e.g. Anaplasma
A61K39/02M:	. . Mollicutes, e.g. Mycoplasma, Erysipelothrix
A61K39/02T:	. . Enterobacteriales, e.g. Enterobacter
A61K39/02T1:	. . . Escherichia
A61K39/02T2:	. . . Klebsiella
A61K39/02T3:	. . . Salmonella
A61K39/02T4:	. . . Shigella
A61K39/02T5:	. . . [N: Yersinia]
A61K39/04:	. . Mycobacterium, e.g. Mycobacterium tuberculosis
A61K39/05:	. . Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella , Corynebacterium; Propionibacterium Mycobacterium A61K39/04
A61K39/07:	. . Bacillus
A61K39/08:	. . Clostridium, e.g. Clostridium tetani
A61K39/085:	. . Staphylococcus
A61K39/09:	. . Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus , streptococcus
A61K39/095:	. . Neisseria
A61K39/098:	. . [N: Brucella]
A61K39/099:	. . [N: Bordetella]
A61K39/09A:	. . . Streptococcus
A61K39/10:	. . Brucella; Bordetella, e.g. Bordetella pertussis
A61K39/102:	. . Pasteurellales, e.g. Actinobacillus , Pasteurella; Haemophilus
A61K39/104:	. . Pseudomonadales, e.g. Pseudomonas
A61K39/104M:	. . . Moraxella
A61K39/105:	. . [N: Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter]
A61K39/106:	. . Vibrio; Campylobacter
A61K39/106C:	. . . Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. Campylobacter, Heliobacter[N0509]
A61K39/106V:	. . . Vibrio[N0509]
A61K39/107:	. . [N: Vibrio]
A61K39/10A:	. . . Brucella[N0509]
A61K39/10B:	. . . Bordetella[N0509]
A61K39/114:	. . Fusobacterium
A61K39/116:	. . Polyvalent bacterial antigens
A61K39/118:	. . Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
A61K39/12:	. Viral antigens
A61K39/125:	. . Picornaviridae, e.g. calicivirus
A61K39/13:	. . . Poliovirus
A61K39/135:	. . . Foot- and mouth-disease virus
A61K39/145:	. . Orthomyxoviridae, e.g. influenza virus
A61K39/15:	. . Reoviridae, e.g. calf diarrhea virus
A61K39/155:	. . Paramyxoviridae, e.g. parainfluenza virus
A61K39/165:	. . . Mumps or measles virus
A61K39/17:	. . . Newcastle disease virus
A61K39/175:	. . . Canine distemper virus
A61K39/187:	. . Hog cholera virus
A61K39/193:	. . Equine encephalomyelitis virus
A61K39/20:	. . Rubella virus
A61K39/205:	. . Rhabdoviridae, e.g. rabies virus
A61K39/21:	. . Retroviridae, e.g. equine infectious anemia virus
A61K39/215:	. . Coronaviradae, e.g. avian infectious bronchitis virus
A61K39/225:	. . . Porcine transmissible gastroenteritis virus
A61K39/23:	. . Parvoviridae, e.g. feline panleukopenia virus
A61K39/235:	. . Adenoviridae
A61K39/245:	. . Herpetoviridae, e.g. herpes simplex virus
A61K39/25:	. . . Varicella-zoster virus
A61K39/255:	. . . Marek`s disease virus
A61K39/265:	. . . Infectious rhinotracheitis virus
A61K39/27:	. . . Equine rhinopneumonitis virus
A61K39/275:	. . Poxviridae, e.g. avipoxvirus
A61K39/285:	. . . Vaccinia virus or variola virus
A61K39/29:	. . Hepatitis virus
A61K39/295:	. . Polyvalent viral antigens ; Mixtures of viral and bacterial antigens
A61K39/29B:	. . . Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
A61K39/35:	. Allergens
A61K39/36:	. . from pollen
A61K39/38:	. Antigens from snakes
A61K39/385:	. Haptens or antigens, bound to carriers
A61K39/39:	. characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K39/395:	. Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K39/395A:	. . from milk, i.e. lactoglobulins
A61K39/395B:	. . from serum, plasma
A61K39/395B1:	. . . Purification
A61K39/395C:	. . against materials from animals
A61K39/395C1:	. . . against normal tissues, cells
A61K39/395C2:	. . . against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K39/395C3:	. . . against tumor tissues, cells, antigens
A61K39/395C4:	. . . against immunoglobulins, e.g. anti-idiotypic antibodies
A61K39/395D:	. . against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
A61K39/395E:	. . against materials not provided for elsewhere, e.g. haptens, coenzymes
A61K39/395S:	. . Stabilisation, fragmentation
A61K39/40:	. . bacterial
A61K39/42:	. . viral
A61K39/44:	. . Antibodies bound to carriers
A61K41/00:	Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
A61K41/00D:	. Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
A61K41/00H:	. Inactivation or decontamination of a medicinal preparation prior to administration to the animal or human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation [M1207]
A61K41/00H4:	. . by ultrasonic waves
A61K41/00H6:	. . by UV, IR, Rx or gamma rays
A61K41/00K:	. Agression treatment or altering [M1207]
A61K41/00M:	. [N: Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation; e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds]
A61K41/00M4:	. . [N: Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds (ultrasound therapy per se A61N7/00)]
A61K41/00P:	. [N: Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10]
A61K41/00R:	. [N: Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion]
A61K41/00T:	. Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent [M1207]
A61K41/00U:	. Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
A61K41/00W:	. [N: Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent]
A61K41/00W10:	. . [N: PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines]
A61K41/00W16:	. . Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
A61K41/00W4:	. . [N: 5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA]
A61K41/00W8:	. . [N: Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins]
A61K41/00W9:	. . [N: PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines]
A61K41/00Y:	. [N: Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation]
A61K41/00Z:	. [N: Neutron capture therapy, e.g. using uranium or non-boron material]
A61K41/00Z4:	. . [N: Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins]
A61K45/00:	Medicinal preparations containing active ingredients not provided for in groups A61K31/00 to A61K41/00
A61K45/05:	. IPC6 Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
A61K45/06:	. Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K47/00:	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
A61K47/02:	. Inorganic compounds
A61K47/06:	. Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
A61K47/08:	. . containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
A61K47/10:	. . . Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycol PEG); Poloxamers; PEG/POE alkyl ethers (sugar alcohols A61K47/26; copolymers containing polyalkylene glycol or poloxamer A61K47/34
A61K47/12:	. . . Carboxylic acids; Salts or anhydrides thereof
A61K47/14:	. . . Esters of carboxylic acids e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens
A61K47/16:	. . containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
A61K47/18:	. . . Amines; Quaternary ammonium compounds, e.g. amides, ureas
A61K47/18B:	. . . . Amino acids or aminosulphonic acids, e.g. glycine, EDTA, aspartame
A61K47/18D:	. . . . Quaternary ammonium compounds, e.g. benzalkonium chloride, cetrimide
A61K47/20:	. . containing sulfur, e.g. DMSO, docusate, sodium lauryl sulfate A61K47/18B, A61K47/18D take precedence
A61K47/22:	. . Heterocyclic compounds, e.g. ascorbic acid, tocopherol, pyrrolidones A61K47/18B, A61K47/18D take precedence
A61K47/24:	. . containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone, phospholipids
A61K47/26:	. . Carbohydrates, e.g. mono-, di-, oligosaccharides, nucleic acids, sugar alcohols, amino sugars; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters, glycyrrhizin A61K47/18B, A61K47/18D take precedence
A61K47/28:	. . Steroids, e.g. cholesterol, bile acids, glycyrrhetinic acid A61K47/18B, A61K47/18D take precedence
A61K47/30:	. Macromolecular compounds
A61K47/32:	. . Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, polyvinyl pyrrolidone
A61K47/34:	. . Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, copolymers of polyalkylene glycol or poloxamer PEG or poloxamers A61K47/10
A61K47/36:	. . Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar, pectin
A61K47/38:	. . . Cellulose; Derivatives thereof
A61K47/40:	. . . Cyclodextrins; Derivatives thereof cyclodextrin inclusion compounds A61K47/48W18B
A61K47/42:	. . Proteins; Polypeptides; Degradation products thereof; Derivatives thereof e.g. albumin, gelatin, zein oligopeptides having up to 5 amino acids A61K47/18B; polyamino acids A61K47/34
A61K47/44:	. Oils, fats or waxes according to more than one of groups A61K47/02 to A61K47/42 ; Natural or modified natural oils, fats or waxes, e.g. polyethoxylated) castor oil, montan wax, ozokerite, lignite, shellac, rosin, beeswax, lanolin (synthetic glycerides, e.g. medium-chain triglycerides A61K47/14
A61K47/46:	. Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fiber, eggshell, oxgall, plant extracts
A61K47/48:	. the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K47/48H:	. . the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
A61K47/48H2:	. . . the modifying agent being an inorganic compound; e.g. inorganic ion that being chemically complexed with the pharmacologically- or therapeutically-active agent A61K47/48H4W takes precedence
A61K47/48H4:	. . . [N: the modifying agent being an organic compound (A61K47/48H4W takes precedence)]
A61K47/48H4A:	. . . . [N: the modifying agent being an organic ion that forms an ion pair complex with the pharmacologically or therapeutically active agent.]
A61K47/48H4C:	. . . . the modifying agent being a carboxylic acid, e.g. a fatty acid or an amino acid
A61K47/48H4F:	. . . . the modifying agent being a lipid, e.g. a triglyceride; the modifying agent being a polyamine, e.g. spermine or spermidine
A61K47/48H4F4:	. . . . . [N: the modifying agent being a phospholipid.]
A61K47/48H4H:	. . . . [N: the modifying agent being a heterocyclic compound (A61K47/48H4V takes precedence)]
A61K47/48H4H4:	. . . . . the modifying agent being a heterocyclic compound which being a porphyrine or a porphyrine with an expanded ring system, e.g. texaphyrine
A61K47/48H4K:	. . . . the modifying agent being a chelate, i.e. single central atom/ion sequestered by a polydentate ligand, e.g. Gd-DOTA or Zinc-amino acid chelate, or a chelate-forming compound, i.e. chelating group, e.g. DOTA or ethylenediamine, that being covalently/complexed to the pharmacologically- or therapeutically-active agent
A61K47/48H4L:	. . . . the modifying agent being a phosphate or phosphonate not being a phospholipid, e.g. bone-seeking
A61K47/48H4M:	. . . . Codrugs[N0508]
A61K47/48H4M12:	. . . . . Antibiotic carriers[N0508]
A61K47/48H4M4:	. . . . . Sugars; Nucleic acids[N0508]
A61K47/48H4M8:	. . . . . Vitamin carriers, e.g. vitamin B12, vitamin A, retinoic acid[N0508]
A61K47/48H4N:	. . . . Steroids, including plant sterols, glycyrrhetic acid[N0508]
A61K47/48H4P:	. . . . [N: the modifying agent linked to the pharmacologically or therapeutically active agent being a sugar, nucleoside, nucleotide, nucleic acid][N: Note nucleic acids can be coding, non-coding, nucleic acid which being therapeutically-active or not, e.g.: oligonucleotides, DNA, RNA, siRNA, nucleic acid aptamers]
A61K47/48H4Q:	. . . . [N: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds, e.g. a polymer of aspirin][N: Note a sugar, nucleoside, nucleotide, nucleic acid is classified in A61K47/48H4P; a polymer of an active agent is not classified in A6K47/48K6]
A61K47/48H4Q12:	. . . . . [N: one of the codrug's components being an antibiotic]
A61K47/48H4Q8:	. . . . . [N: one of the codrug's components being a vitamin, e.g. niacinamide (vitamin B3), cobalamin (vitamin B12), folate, vitamin A, retinoic acid]
A61K47/48H4R:	. . . . the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone, bile acid
A61K47/48H4S:	. . . . pretargeting systems involving an organic compound, not being a peptide, protein or antibody, for targeting specific cells
A61K47/48H4S4:	. . . . . ECTA, enzyme catalyzed therapeutic agent
A61K47/48H4S8:	. . . . . the modifying agent being biotin
A61K47/48H4V:	. . . . the modifying agent being a chemiluminescent acceptor
A61K47/48H4W:	. . . . Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
A61K47/48K:	. . the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
A61K47/48K4:	. . . [N: the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol]
A61K47/48K4D:	. . . . [N: the macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds being an ion exchange resin, e.g. polystyrene sulfonic acid resin]
A61K47/48K6:	. . . [N: the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes]
A61K47/48K6E:	. . . . [N: the macromolecule is/contains a polyester, e.g. PLGA, polylactide-co-glycolide]
A61K47/48K6F:	. . . . [N: the macromolecule is/contains a polyamide, e.g. nylon (polyamino acids A61K47/48R)]
A61K47/48K6P:	. . . . the organic macromolecular compound being a polyoxyalkylene oligomer, polymer, dendrimer, e.g. PEG, PPG, PEO, polyglycerol
A61K47/48K6Z:	. . . . [N: the macromolecule contains phosphorus in the main chain, e.g. poly-phosphazene]
A61K47/48K8:	. . . the organic macromolecular compound being a polysaccharide or a derivative, e.g. starch, chitosan, chitin, cellulose, pectin, cyclodextrin with the pharmacologically active agent being covalently linked to the external surface of the ring structure, a bacterial polysaccharide or oligosaccharide antigen, a glycosaminoglycan
A61K47/48R:	. . the modifying agent being a protein, peptide, polyamino acid
A61K47/48R2:	. . . [N: drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
A61K47/48R2B:	. . . . [N: the peptide, protein or polyamino acid in the drug conjugate being a branched, dendritic or hypercomb peptide]
A61K47/48R2D:	. . . . [N: the peptide or protein in the drug conjugate being a toxin or a lectin, e.g. clostridial toxins or Pseudomonas exotoxin]
A61K47/48R2F:	. . . . the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors, interferons being the inactive part of the conjugate
A61K47/48R2H:	. . . . the peptide or protein in the drug conjugate being a receptor as such, e.g. CD4; a cell surface antigen (therefore not a peptide ligand targeting the antigen); a cell surface determinant, i.e. a part of the surface of a cell
A61K47/48R2L:	. . . . [N: the peptide or protein in the drug conjugate being an albumin, e.g. HSA, BSA, ovalbumin, or a Keyhole Limpet Hemocyanin (KHL)]
A61K47/48R2N:	. . . . [N: the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin, gelatin]
A61K47/48R2P:	. . . . [N: the peptide or protein in the drug conjugate being a transferrin, e.g. a lactoferrin or ovotransferrin]
A61K47/48R2R:	. . . . [N: the peptide or protein in the drug conjugate being a haemoglobin]
A61K47/48R2T:	. . . . [N: the peptide or protein in the drug conjugate being a polycationic or polyanionic oligopeptide, polypeptide or polyamino acid, e.g. polylysine, polyarginine, polyglutamic acid, peptide TAT]
A61K47/48R2T2:	. . . . . [N: polyanionic oligopeptide, polypeptide or polyamino acid, used to complex nucleic acids being the therapeutic agent]
A61K47/48R2V:	. . . . the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
A61K47/48R4:	. . . [N: peptidic linker, binder, spacer, e.g. peptidic enzyme-labile linker]
A61K47/48R6:	. . . pretargeting systems involving a peptide or protein not an antibody A61K47/48T8 for targeting specific cells
A61K47/48R6D:	. . . . [pretargeting system, clearing therapy or rescue therapy involving biotin-(strept)avidin systems]
A61K47/48R6F:	. . . . Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy (GDEPT), VDEPT
A61K47/48T:	. . the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
A61K47/48T2:	. . . drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
A61K47/48T2C:	. . . . drug conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
A61K47/48T2C12:	. . . . . [N: the drug being a protein or peptide, e.g. transferrin or bleomycin]
A61K47/48T2C12K:	. . . . . . [N: the drug being a peptidic cytokine, e.g. an interleukin or interferon]
A61K47/48T2C12M:	. . . . . . [N: the drug being an enzyme]
A61K47/48T2C12P:	. . . . . . [N: the drug being a toxin]
A61K47/48T2C12P2:	. . . . . . . [N: the drug being a plant toxin]
A61K47/48T2C12P2D:	. . . . . . . . [N: the drug being a plant heterodimeric toxin; chains A or B containing toxins, e.g. abrin, modeccin]
A61K47/48T2C12P2D2:	. . . . . . . . . [N: the drug being ricin (double chain)]
A61K47/48T2C12P2F:	. . . . . . . . [N: the drug being a ribosomal inhibitory protein, (RIP-i or RIP-II), e.g. Pap, gelonin, dianthin]
A61K47/48T2C12P2F2:	. . . . . . . . . [N: the drug being ricin A]
A61K47/48T2C12P4:	. . . . . . . [N: the drug being a bacterial toxin, e.g. diphteria toxin, Pseudomonas exotoxin A]
A61K47/48T2C12P6:	. . . . . . . [N: the drug being a fungal toxin, e.g. alpha sarcine, mitogillin, zinniol, restrictocin]
A61K47/48T2C12P8:	. . . . . . . [N: the drug being a viral toxin]
A61K47/48T2C2:	. . . . . [N: the drug being a vinca alkaloid]
A61K47/48T2C8:	. . . . . [N: the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense]
A61K47/48T2C8H:	. . . . . . [N: the drug being an antibiotic, e.g. one of the antitumor antibiotics: anthracyclins, adriamycin, doxorubicin, daunomycin]
A61K47/48T4:	. . . the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
A61K47/48T4B:	. . . . not used; see subgroups
A61K47/48T4B10:	. . . . . [N: the antibody being against material from viruses]
A61K47/48T4B10D:	. . . . . . [N: the antibody being targeting a RNA virus]
A61K47/48T4B18:	. . . . . [N: the antibody being targeting a material from animals or humans.]
A61K47/48T4B24:	. . . . . [N: the antibody being targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon]
A61K47/48T4B26:	. . . . . [N: the antibody being targeting an hormone, or an hormone-releasing or -inhibiting factor]
A61K47/48T4B28:	. . . . . [N: the antibody being targeting a receptor, a cell surface antigen, a cell surface determinant]
A61K47/48T4B30:	. . . . . [N: the antibody being targeting a determinant of a tumour cell]
A61K47/48T4B30A:	. . . . . . [N: the tumour determinant being carcino-embryonic antigen]
A61K47/48T4B30B:	. . . . . . [N: the tumour determinant being from breast cancer cell]
A61K47/48T4B30D:	. . . . . . [N: the tumour determinant being from lung cancer cell]
A61K47/48T4B30F:	. . . . . . [N: the tumour determinant being from liver or pancreas cancer cell]
A61K47/48T4B30H:	. . . . . . [N: the tumour determinant being from kidney or bladder cancer cell]
A61K47/48T4B30K:	. . . . . . [N: the tumour determinant being from stomach or intestines cancer cell]
A61K47/48T4B30L:	. . . . . . [N: the tumour determinant being from skin, nerves or brain cancer cell]
A61K47/48T4B30M:	. . . . . . [N: the tumour determinant being from a cell of a blood cancer]
A61K47/48T4B30P:	. . . . . . [N: the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate]
A61K47/48T4B40:	. . . . . [N: the antibody being targeting an enzyme]
A61K47/48T4B42:	. . . . . [N: the antibody being targeting an immunoglobulin, being an anti-idiotypic antibody]
A61K47/48T4B46:	. . . . . [N: the antibody being a hybrid immunoglobulin]
A61K47/48T4B46B:	. . . . . . [N: the antibody being an immunoglobulin containing regions, domains, residues from different species]
A61K47/48T4B46D:	. . . . . . [N: the immunoglobulin has two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin]
A61K47/48T4F:	. . . . [N: cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies that are covalently linked to each other, or of different antigen-binding fragments fragments that are covalently linked to each other]
A61K47/48T4K:	. . . . [N: polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate, used for therapy]
A61K47/48T4K2:	. . . . . [N: the conjugate or the polymer being a starburst, a dendrimer, a cascade]
A61K47/48T4M:	. . . . [N: antibody-chelate conjugate wherein the chelate being used for therapeutic purposes (when radioabeled and used in radiodiagnosis or radiotherapy A61K51/10Z and the corresponding A61K51/10B subgroup; antibody-chelate used for MRI A61K49/14)]
A61K47/48T6:	. . . [N: conjugates wherein the antibody being the modifying agent and wherein the linker, binder, spacer confers particular properties to the conjugate, e.g. peptidic enzyme-labile linker or acid-labile linker giving rise to an acid-labile immunoconjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural, environment]
A61K47/48T8:	. . . pretargeting systems involving an antibody for targeting specific cells
A61K47/48T8B:	. . . . [N: clearing therapy or enhanced clearance, i.e. wherein an antibody clearing agent being used in addition to T-A and D-M according to the definitions in A61K47/48T8]
A61K47/48T8F:	. . . . [N: rescue therapy; agonist-antagonist; antidote; targeted rescue or protection e.g. folic acid-folinic acid, conjugated to antibodies both or only one]
A61K47/48T8M:	. . . . [N: two or three steps pretargeting systems, wherein an antibody conjugate being used in at least one of the steps; ligand-antiligand therapy]
A61K47/48T8M4:	. . . . . avidin-biotin system wherein at least one avidin- or biotin-conjugated antibody being used in a two- or three-steps pretargeting system
A61K47/48T8P:	. . . . ADEPT, i.e. Antibody Directed Enzyme Prodrug Therapy
A61K47/48W:	. . the conjugate being characterized by a special physical or galenical form
A61K47/48W10:	. . . [N: the form being a pill, tablet, lozenge, capsule]
A61K47/48W14:	. . . Microcapsules
A61K47/48W14B:	. . . . Nanocapsules; Nanoparticles, e.g. immunonanoparticles
A61K47/48W18:	. . . [N: the conjugate being in the form of a host-guest, i.e. being an inclusion complex, e.g. clathrate, cavitate, fullerene]
A61K47/48W18B:	. . . . [N: inclusion being performed with a cyclodextrin (cyclodextrins used as simple excipients A61K47/40)]
A61K47/48W2:	. . . forms of ingredients not provided for by groups A61K47/48W4 to A61K47/48W26, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent
A61K47/48W22:	. . . [N: the form being a fibre, textile, slabb, sheet]
A61K47/48W24:	. . . [N: the form being a plaster, bandage, dressing, patch]
A61K47/48W26:	. . . [N: the form being a device, kit .e.g. stent, microdevice]
A61K47/48W4:	. . . [N: the form being semi-solid, an ointment, a gel, a hydrogel, a solidifying gel]
A61K47/48W6:	. . . [N: the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension]
A61K47/48W6B:	. . . . the form being a micro-emulsion, nano-emulsion or micelle Simple encapsulation of a drug in micelle: A61K9/107D
A61K47/48W6B2:	. . . . . [N: micelles formed by phospholipids]
A61K47/48W6D:	. . . . the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent. Simple encapsulation of a drug which being not functionalised on its surface by a modifying agent: see A61K9/127
A61K47/48W6D2:	. . . . . the form being a liposome which being modified on its surface by an antibody
A61K47/48W6D4:	. . . . . [N: the form being a polymersome, i.e. a liposome with polymerisable or polymerized bilayer-forming substances][N: Note Liposomes comprising polymers grafted on their surface are not classified in A61K47/48W6D4, but in A61k47/48W6D if the polymer being unusual, or in A61K9/127B]
A61K47/48W6G:	. . . . [N: the form being a lipoprotein vesicle, e.g. HDL and LDL proteins]
A61K47/48W6H:	. . . . the form being a ribbon, tubule cochleate
A61K47/48W8:	. . . the form being a particulate, powder, adsorbate, bead, sphere
A61K47/48W8B:	. . . . the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
A61K47/48W8D:	. . . . the form being a micro- or nano-capsule or a micro/nano-bubble, i.e. a hollow or gas micro- or nano-particle or sphere, a gas-filled micro- or nano-particle for use in therapy Micro- or nano-bubbles used only for ultrasound imaging are classified in A61K49/22P4 or A61K49/22P8 only
A61K47/48W8E:	. . . . [N: the form being a solid microparticle having no hollow or gas-filled core][N: Note Its size or diameter being higher or equal to 1 micrometer]
A61K47/48W8E2:	. . . . . [N: the form being a nanoparticle, e.g. an immuno-nanoparticle][N: Note Its size or diameter being smaller than 1 micrometer. Classification being also made according to the nature of the antibody with the appropriate A61K47/48T4B subgroup]
A61K47/48W8E2K:	. . . . . . [N: the material constituting the nanoparticle being a polymer][N: Note The subgroups A61K47/48K are not additionally used]
A61K47/48W8E2K4:	. . . . . . . [N: the material constituting the nanoparticle being a polymer obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone, polyvinylalcohol]
A61K47/48W8E2K6:	. . . . . . . the material constituting the nanoparticle being a polymer obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides, polyglycerol
A61K47/48W8E2K6G:	. . . . . . . . the polymer being PLGA, PLA or polyglycolic acid
A61K47/48W8E2K8:	. . . . . . . [N: the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose, pectin]
A61K47/48W8F:	. . . . [N: the form being a granulate or an agglomerate]
A61K48/00:	Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K48/00B:	. characterised by an aspect of the `non-active` part of the composition delivered, e.g. wherein such `non-active` part is not delivered simultaneously with the `active` part of the composition
A61K48/00B2:	. . wherein the nucleic acid is delivered as a `naked` nucleic acid, i.e. not combined with an entity such as a cationic lipid
A61K48/00B4:	. . wherein the non-active part clearly interacts with the delivered nuclic acid
A61K48/00B4A:	. . . the non-active part being non-polymeric
A61K48/00B4B:	. . . the non-active part being polymeric
A61K48/00D:	. characterised by an aspect of the `active` part of the composition delivered, i.e. the nucleic acid delivered
A61K48/00D2:	. . Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
A61K48/00D4:	. . Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
A61K48/00F:	. characterised by an aspect of the delivery route, e.g. oral, subcutaneous
A61K48/00H:	. characterised by an aspect of the administration regime
A61K48/00J:	. Purification or manufacturing processes for gene therapy compositions
A61K49/00:	Preparations for testing in vivo
A61K49/00F:	. General or multifunctional contrast agents, e.g. chelated agents
A61K49/00H:	. Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
A61K49/00H4:	. . Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
A61K49/00H6:	. . Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
A61K49/00P:	. Preparation for luminescence or biological staining
A61K49/00P12:	. . characterised by a special physical or galenical form, e.g. emulsions, microspheres
A61K49/00P12B:	. . . the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
A61K49/00P12B2:	. . . . quantum dots, fluorescent nanocrystals
A61K49/00P12C:	. . . the agent being in a particular physical galenical form
A61K49/00P12C10:	. . . . Particulate, powder, adsorbate, bead, sphere
A61K49/00P12C10C:	. . . . . Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
A61K49/00P12C10C2:	. . . . . . Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
A61K49/00P12C10C2B:	. . . . . . . Nanotubes
A61K49/00P12C12:	. . . . Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
A61K49/00P12C2:	. . . . solution, solute
A61K49/00P12C4:	. . . . semi-solid, gel, hydrogel, ointment
A61K49/00P12C8:	. . . . dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
A61K49/00P12C8B:	. . . . . micro-emulsion, nano-emulsion
A61K49/00P12C8D:	. . . . . lipoprotein vesicle, e.g. HDL or LDL proteins
A61K49/00P12C8E:	. . . . . micelle, e.g. phospholipidic micelle and polymeric micelle
A61K49/00P12C8F:	. . . . . liposome, i.e. bilayered vesicular structure
A61K49/00P12C8F2:	. . . . . . Polymersome, i.e. liposome with polymerisable or polymerized bilayered-forming substances
A61K49/00P4:	. . Luminescence
A61K49/00P4C:	. . . Phosphorescence
A61K49/00P4F:	. . . Fluorescence in vivo
A61K49/00P4F4:	. . . . characterised by the fluorescent group
A61K49/00P4F4C:	. . . . . the fluorescent group being a small organic molecule oligomeric, polymeric, dendritic molecules: A61K49/00P4F4
A61K49/00P4F4C10:	. . . . . . Methine dyes, e.g. cyanine dyes
A61K49/00P4F4C10C:	. . . . . . . Indocyanine green, i.e. ICG, cardiogreen üC1206]
A61K49/00P4F4C12:	. . . . . . Porphyrins used in photodynamic therapy A61K41/00W9 or A61K41/00W10; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/48H4H4
A61K49/00P4F4C14:	. . . . . . Coumarin dyes
A61K49/00P4F4C16:	. . . . . . Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N)
A61K49/00P4F4C16F:	. . . . . . . Fluorescein, used in vivo
A61K49/00P4F4C2:	. . . . . . Di-or triarylmethane dye xanthene dyes A61K49/00P4F4C16
A61K49/00P4F4C4:	. . . . . . Acridine dyes
A61K49/00P4F4C6:	. . . . . . Oxazine dyes
A61K49/00P4F4C8:	. . . . . . Thiazine dyes
A61K49/00P4F4P:	. . . . . the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
A61K49/00P4F4P4:	. . . . . . Green fluorescent protein (GFP)
A61K49/00P4F8:	. . . . characterised by the carrier molecule carrying the fluorescent agent
A61K49/00P4F8H:	. . . . . Small organic molecules oligomers, polymers, dendrimers A61K49/00P4F8K
A61K49/00P4F8K:	. . . . . Macromolecular compounds, i.e. oligomers, polymers, dendrimers
A61K49/00P4F8R:	. . . . . Peptides, proteins, polyamino acids
A61K49/00P4F8T:	. . . . . Antibodies
A61K49/00P8:	. . Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
A61K49/04:	. X-ray contrast preparations
A61K49/04B:	. . containing barium sulfate
A61K49/04F:	. . Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
A61K49/04F8:	. . . Particles, beads, capsules or spheres
A61K49/04F8M:	. . . . Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
A61K49/04F8N:	. . . . Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
A61K49/04F8N2:	. . . . . Surface-modified nanoparticles, e.g. immuno-nanoparticles
A61K49/04H:	. . containing an organic halogenated X-ray contrast-enhancing agent
A61K49/04H2:	. . . Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
A61K49/04H4:	. . . Polymeric X-ray contrast-enhancing agent comprising a halogenated group
A61K49/04H8:	. . . Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
A61K49/04H8B:	. . . . Solutions, e.g. for injection
A61K49/04H8D:	. . . . Semi-solid forms, ointments, gels, hydrogels
A61K49/04H8F:	. . . . Dispersions, colloids, emulsions or suspensions
A61K49/04H8F2:	. . . . . Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
A61K49/04H8F6:	. . . . . Perflubron, i.e. perfluoroctylbromide, C8F17Br emulsions
A61K49/04H8P:	. . . . Particles, beads, capsules, spheres
A61K49/04H8P2:	. . . . . Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
A61K49/04H8P4:	. . . . . Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
A61K49/04H8P4S:	. . . . . . Surface-modified nanoparticles, e.g. immune-nanoparticles
A61K49/04H8T:	. . . . intended for oral administration
A61K49/06:	. Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
A61K49/08:	. . characterised by the carrier
A61K49/08Z:	. . . conjugated systems
A61K49/10:	. . . Organic compounds
A61K49/10C:	. . . . [N: the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
A61K49/10C4:	. . . . . the complex-forming compound being acyclic, e.g. DTPA
A61K49/10C4G:	. . . . . . the metal complex being Gd-DTPA
A61K49/10C8:	. . . . . the complex-forming compound being cyclic, e.g. DOTA
A61K49/10C8G:	. . . . . . the metal complex being Gd-DOTA
A61K49/12:	. . . . Macromolecular compounds
A61K49/12D:	. . . . . dimers of complexes or complex-forming compounds
A61K49/12H:	. . . . . dendrimers, dendrons, hyperbranched compounds
A61K49/12P:	. . . . . Linear polymers, e.g. dextran, inulin, PEG
A61K49/12P4:	. . . . . . comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
A61K49/14:	. . . . Peptides, e.g. proteins
A61K49/14L:	. . . . . the protein being an albumin, e.g. HSA, BSA, ovalbumin
A61K49/14T:	. . . . . the peptide being a polyamino acid, e.g. poly-lysine
A61K49/16:	. . . . . Antibodies; Immunoglobulins; Fragments thereof
A61K49/18:	. . characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A61K49/18F:	. . . Semi-solid preparations, e.g. ointments, gels, hydrogels
A61K49/18K:	. . . Suspensions, emulsions, colloids, dispersions
A61K49/18K12:	. . . . compo-inhalant, e.g. breath tests
A61K49/18K4:	. . . . Micelles, e.g. phospholipidic or polymeric micelles
A61K49/18K8:	. . . . liposomes, polymersomes, e.g. immunoliposomes
A61K49/18P:	. . . Particles, e.g. microparticles, microspheres[N0201]
A61K49/18P2:	. . . . Clusters[N0201]
A61K49/18P4:	. . . . Composites[N0201]
A61K49/18P6:	. . . . Coated particles[N0201]
A61K49/18P8:	. . . . Nanoparticles[N0201]
A61K49/18R:	. . . particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
A61K49/18R2:	. . . . coated or functionalised microparticles or nanoparticles
A61K49/18R2N:	. . . . . coated or functionalised nanoparticles liposomes A61K49/18K8; nano-emulsions A61K49/18K; micelles A61K49/18K4
A61K49/18R2N2:	. . . . . . having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
A61K49/18R2N2B:	. . . . . . . having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
A61K49/18R2N2H:	. . . . . . . having a super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K49/18R2N2K
A61K49/18R2N2H10:	. . . . . . . . the small organic molecule being a silane
A61K49/18R2N2H2:	. . . . . . . . the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
A61K49/18R2N2H4:	. . . . . . . . the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
A61K49/18R2N2H6:	. . . . . . . . the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
A61K49/18R2N2H8:	. . . . . . . . the small organic molecule being a carbohydrate (monosaccharides, discacharides)
A61K49/18R2N2K:	. . . . . . . having a super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule (peptide or protein A61K49/18R2N2R; polyamino acid A61K49/18R2N2R4; antibody A61K49/18R2N2T
A61K49/18R2N2K4:	. . . . . . . . the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
A61K49/18R2N2K6:	. . . . . . . . the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
A61K49/18R2N2K6A:	. . . . . . . . . the organic macromolecular compound being polyethyleneglycol (PEG)
A61K49/18R2N2K8:	. . . . . . . . the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
A61K49/18R2N2R:	. . . . . . . the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
A61K49/18R2N2R2:	. . . . . . . . coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin
A61K49/18R2N2R4:	. . . . . . . . coated or functionalised with a polyamino acid, e.g. polylysine, polyglutamic acid
A61K49/18R2N2T:	. . . . . . . coated or functionalised with an antibody
A61K49/18R2N4:	. . . . . . the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
A61K49/18R2N4C:	. . . . . . . wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
A61K49/18R4:	. . . . Nanotubes, nanorods or nanowires
A61K49/18R6:	. . . . Agglomerates, clusters, i.e. more than one (super)(para)magnetic microparticle or nanoparticle are aggregated or entrapped in the same maxtrix
A61K49/18T:	. . . Host-guest complexes, e.g. cyclodextrins
A61K49/18T4:	. . . . Molecular sieves
A61K49/18W:	. . . not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
A61K49/20:	. . containing free radicals e.g. trityl radical for overhauser
A61K49/22:	. Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations
A61K49/22C:	. . characterised by the targeting agent or modifying agent linked to the acoustically-active agent
A61K49/22P:	. . characterised by a special physical form, e.g. emulsions, liposomes
A61K49/22P12:	. . . Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
A61K49/22P16:	. . . Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
A61K49/22P20:	. . . Host-guest complexes, clathrates, chelates
A61K49/22P4:	. . . Micro-bubbles, hollow microspheres, free gas bubbles, gas microspheres
A61K49/22P8:	. . . Microparticles, microcapsules gas-filled to be classified in A61K49/22P4
A61K51/00:	Preparations containing radioactive substances for use in therapy or testing in vivo
A61K51/02:	. characterised by the carrier, [N: i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus]
A61K51/02B:	. . [N: inorganic Tc complexes or compounds]
A61K51/04:	. . organic compounds
A61K51/04B:	. . . [N: carboxylic acid carriers, fatty acids (amino acids A61K51/04D4)]
A61K51/04D:	. . . [N: Lipids, e.g. triglycerides; Polycationic carriers (fatty acids A61K51/04B; cholesterol A61K51/04S; polycationic carriers being oligomers, polymers, dendrimers A61K47/48K)]
A61K51/04D4:	. . . . [N: Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines]
A61K51/04D8:	. . . . [N: Phospholipids (liposomes encapsulating the radioactive probe or having no radiolabelled phospholipids A61K51/12E8)]
A61K51/04F:	. . . Porphyrins[N9409]
A61K51/04G:	. . . Heterocyclic compounds.
A61K51/04G12:	. . . .  Tropane or nortropane groups, e.g. cocaine
A61K51/04G20:	. . . . [N: having oxygen as the only ring hetero atom, e.g. fungichromin]
A61K51/04G20B:	. . . . . [N: having three-membered rings, e.g. oxirane, fumagillin]
A61K51/04G20D:	. . . . . [N: having four-membered rings, e.g. taxol]
A61K51/04G20F:	. . . . . [N: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide]
A61K51/04G20H:	. . . . . [N: having six-membered rings with one oxygen as the only ring hetero atom]
A61K51/04G20L:	. . . . . [N: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel]
A61K51/04G20M:	. . . . . [N: compounds containing methylenedioxyphenol groups, e.g. sesamin]
A61K51/04G20P:	. . . . . [N: Lactones]
A61K51/04G4:	. . . .  Benzodiazepines
A61K51/04G40:	. . . . [N: having sulfur as a ring hetero atom]
A61K51/04G40B:	. . . . . [N: having five-membered rings]
A61K51/04G40F:	. . . . . [N: having six-membered rings, e.g. thioxanthenes (thiotixene A61K51/04G60M)]
A61K51/04G40K:	. . . . . [N: having two or more sulfur atoms in the same ring]
A61K51/04G40P:	. . . . . [N: having oxygen in the same ring]
A61K51/04G60:	. . . . [N: having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins (rifampin A61K51/04G60M)]
A61K51/04G60B:	. . . . . [N: having three-membered rings, e.g. aziridine]
A61K51/04G60D:	. . . . . [N: having four-membered rings, e.g. azetidine]
A61K51/04G60F:	. . . . . [N: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil]
A61K51/04G60F4:	. . . . . . [N: tropane or nortropane groups, e.g. cocaine]
A61K51/04G60F8:	. . . . . . having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine hemin, hematin A61K51/04G80
A61K51/04G60H:	. . . . . [N: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole]
A61K51/04G60K:	. . . . . [N: having six-membered rings with one nitrogen as the only ring hetero atom]
A61K51/04G60K4:	. . . . . . [N: Vesamicol]
A61K51/04G60M:	. . . . . [N: having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine]
A61K51/04G60P:	. . . . . [N: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K51/04G80)]
A61K51/04G60S:	. . . . . [N: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines]
A61K51/04G60T:	. . . . . [N: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame]
A61K51/04G60X:	. . . . . [N: having seven-membered rings, e.g. azelastine, pentylenetetrazole]
A61K51/04G60X4:	. . . . . . [N: Benzodiazepines]
A61K51/04G8:	. . . .  Vesamicol
A61K51/04G80:	. . . . [N: containing heavy metals, e.g. hemin, hematin, melarsoprol]
A61K51/04H:	. . .  Sugars[N9409][C1204]
A61K51/04K:	. . . Steroids[N9409]
A61K51/04L:	. . . complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by e.g. a N2S2, N3S, NS3, N4 chelating group [M1205]
A61K51/04L12:	. . . . [N: chelates from cyclic ligands, e.g. DOTA]
A61K51/04L16:	. . . . Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal [M1205]
A61K51/04L20:	. . . . [N: Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions]
A61K51/04L4:	. . . . [N: complexes from monodendate ligands, e.g. sestamibi]
A61K51/04L8:	. . . . [N: complexes from non-cyclic ligands, e.g. EDTA, MAG3]
A61K51/04L8D:	. . . . . [N: DTPA (diethylenetriamine tetraacetic acid)]
A61K51/04P:	. . . [N: Phosphates or phosphonates, e.g. bone-seeking phosphonates; (phospholipids: A61K51/04D8; nucleotides or nucleic acids: A61K51/04R)]
A61K51/04R:	. . . [N: Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers]
A61K51/04S:	. . . [N: Steroids, e.g. cholesterol, testosterone]
A61K51/04V:	. . . Pretargeting
A61K51/04Z:	. . . conjugates with a carrier being an organic compounds [M1205]
A61K51/06:	. . . Macromolecular compounds, [N: carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules (peptides, proteins, polyamino acids A61K51/08; antibodies A61K51/10)]
A61K51/06Z:	. . . . conjugates with carriers being macromolecules [M1205]
A61K51/08:	. . . Peptides, e.g. proteins, [N: carriers being peptides, polyamino acids, proteins]
A61K51/08H:	. . . . [N: the protein being an albumin, e.g. human serum albumin (HSA), bovine serum albumin (BSA), ovalbumin]
A61K51/08J:	. . . . [N: the peptide being a RGD-containing peptide]
A61K51/08K:	. . . . [N: the peptide being octreotide or a somatostatin-receptor-binding peptide]
A61K51/08L:	. . . . [N: the peptide being oxytocin]
A61K51/08M:	. . . . [N: the peptide being neurotensin]
A61K51/08N:	. . . . [N: the peptide being alphaMSH, alpha melanocyte stimulating hormone]
A61K51/08P:	. . . . [N: the peptide being an annexin, e.g. annexin V]
A61K51/08Z:	. . . . conjugates with carriers being peptides, polyamino acids, proteins antibodies A61K51/10 [M1205]
A61K51/10:	. . . . Antibodies or immunoglobulins; Fragments thereof, [N: the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody]
A61K51/10B:	. . . . . not used, see subgroups
A61K51/10B12:	. . . . . . [N: against material from bacteria]
A61K51/10B14:	. . . . . . [N: against material from fungi, lichens, algae]
A61K51/10B16:	. . . . . . [N: against material from plants]
A61K51/10B18:	. . . . . . [N: against material from animals or humans]
A61K51/10B24:	. . . . . . [N: against cytokines, e.g. growth factors, VEGF, TNF, lymphokines, interferons]
A61K51/10B26:	. . . . . . [N: against hormones, hormone-releasing or hormone-inhibiting factors]
A61K51/10B28:	. . . . . . [N: against receptors, cell-surface antigens, cell-surface determinants]
A61K51/10B28G:	. . . . . . . [N: against receptors for growth factors or receptors for growth regulators]
A61K51/10B28H:	. . . . . . . [N: against receptors for cytokines, lymphokines, interferons]
A61K51/10B28K:	. . . . . . . [N: against hormone receptors]
A61K51/10B28L:	. . . . . . . [N: against T-cell receptors]
A61K51/10B28L2:	. . . . . . . . against Tcell receptor (TcR)-CD3 complex
A61K51/10B30:	. . . . . . [N: against animal or human tumor cells or tumor cell determinants]
A61K51/10B30A:	. . . . . . . [N: the tumor cell determinant being a carcino embryonic antigen]
A61K51/10B30B:	. . . . . . . [N: the tumor cell being from breast, e.g. the antibody being herceptin]
A61K51/10B30D:	. . . . . . . [N: the tumor cell being from lung]
A61K51/10B30F:	. . . . . . . [N: the tumour cell being from liver or pancreas]
A61K51/10B30H:	. . . . . . . [N: the tumor cell being from kidney, bladder]
A61K51/10B30K:	. . . . . . . [N: the tumor cell being from stomach or intestines]
A61K51/10B30L:	. . . . . . . [N: the tumor cell being from skin]
A61K51/10B30M:	. . . . . . . [N: the tumor cell being from blood cells, e.g. the cancer being a myeloma]
A61K51/10B30P:	. . . . . . . [N: the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes, prostate]
A61K51/10B40:	. . . . . . [N: the antibody being against an enzyme]
A61K51/10B42:	. . . . . . [N: the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody]
A61K51/10B44:	. . . . . . [N: the antibody being against a material not provided elsewhere]
A61K51/10B46:	. . . . . . [N: the antibody being a hybrid immunoglobulin]
A61K51/10B46B:	. . . . . . . [N: the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins]
A61K51/10B46D:	. . . . . . . [N: immunoglobulins having two or more different antigen-binding sites, multifunctional antibodies]
A61K51/10B8:	. . . . . . [N: the antibody being against or targeting material from viruses]
A61K51/10Z:	. . . . . conjugates with carriers being antibodies [M1205]
A61K51/10Z6:	. . . . . . [N: radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/10Z, and including a radioactive nucleus for use in radiotherapeutic applications]
A61K51/12:	. characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, [N: characterized by a special physical form, e.g. emulsions, dispersions, microcapsules (liposomes A61K51/12E12)]
A61K51/12A:	. . in a form not provided for by groups A61K51/12B to A61K51/12W, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
A61K51/12B:	. . [N: Administration of radioactive gases, aerosols or breath tests]
A61K51/12C:	. . [N: Solutions, i.e. homogeneous liquid formulation]
A61K51/12D:	. . [N: Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature]
A61K51/12E:	. . [N: Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols]
A61K51/12E12:	. . . Liposomes Note Liposomes modified on their external surface by a targeting agent, e.g. an antibody, are not additionally classified with the symbol of the targeting agent
A61K51/12E12A:	. . . . [N: Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances]
A61K51/12E2:	. . . [N: Micro-emulsions, nano-emulsions]
A61K51/12E4:	. . . [N: Lipoprotein vesicles, e.g. HDL and LDL proteins]
A61K51/12E6:	. . . [N: Micelles, e.g. phospholipidic or polymeric micelles]
A61K51/12E8:	. . . Aerosols or breath tests, e.g. administration of gasses, emanators
A61K51/12H:	. . [N: particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins]
A61K51/12H2:	. . . [N: micro- particles or nano-particles, e.g. polymeric nanoparticles]
A61K51/12H2A:	. . . . [N: nanotubes]
A61K51/12H2B:	. . . . [N: micro- or nano-spheres, micro- or nano-beads, micro- or nano-capsules]
A61K51/12H4:	. . . Granulates, agglomerates, microspheres
A61K51/12K:	. . Pills, tablets, lozenges
A61K51/12M:	. . Capsules
A61K51/12M4:	. . . Microcapsules
A61K51/12N:	. . [N: host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes]
A61K51/12P:	. . [N: Sponges]
A61K51/12R:	. . [N: Fibers, textiles, slabbs, or sheets]
A61K51/12S:	. . [N: Plasters, bandages, dressings, patches or adhesives]
A61K51/12T:	. . [N: Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents]
A61K51/12T4:	. . . [N: Ampoules, glass carriers carrying the therapeutic or in vivo diagnostic agent]
A61K51/12T8:	. . . [N: Devices or containers for impregnation, for emanation, e.g. bottles or jars for radioactive water for use in radiotherapy]
A61K51/12V:	. . [N: Radioactive cosmetics, e.g. radioactive bathsalts, soaps]
A61K51/12W:	. . [N: Radioactive food, e.g. chocolates, drinks]